Flexible Endoscope Incident Report

Updated November 2018
Table of Contents

1. Failure of Visual Inspection ............................................................... Pages 1-26

1.1. The angulation of the bending section of the Uretero-Reno Fiberscope did not work in the down direction, July 2018

1.2. An employee received a burn on their hand while unloading instruments from their V-Pro Max, June 2018

1.3. A V-Pro Max sterilizer was found to be emitting a mist that filled the room with “haze”, May 2018

1.4. The bending section of the Uretero-Reno Fiberscope broke inside the patient with a non-Olympus laser probe inserted into the channel of the Fiberscope, May 2018

1.5. The shaft of a LithoVue scope used in a Ureteroscopy procedure bent over onto itself and locked during the procedure, May 2018

1.6. Pentax Duodenoscope failed a cleaning verification test three times using 3M Clean Trace and sent to Pentax were several areas of scope had wear and tear, May 2018

1.7. During an unspecified transnasal bronchoscopy, the rhinal mucosa of the patient was injured with a small amount of bleeding, May 2018

1.8. During an unspecified procedure, a wire was found sticking out of the insertion tube, May 2018

1.9. A rubber piece from Ureteroscope fell off inside the patient’s ureter at the beginning of a kidney stone procedure, May 2018

1.10. During the reprocessing of the Ureteroscope, the distal tip was noted to have sharp edges and was found broken, May 2018

1.11. Multiple microbiological testing by the user facility, following microbes were detected from a Bronchovideoscope BF-1T180, May 2018

1.12. An unspecified number of patient infections occurred at a user facility with the use of Olympus Cystoscopes during an unspecified number of procedures, May 2018
1.13. An unspecified number of patient infections occurred at a user facility with the use of Olympus Cystoscopes during an unspecified number of procedures, May 2018

1.14. Several patients became infected after ERCP procedure with the same Duodenoscope, May 2018

1.15. The lens of an ERCP Duodenoscope was discovered to be green, May 2018

1.16. A customer reported an event of a strong odor emitting from the Sterrad® 100NX Sterilizer after the cycle completes, May 2018

1.17. A Cystonephrofiberscope was noted as having approximately 3cm of its covering missing as it was being removed from the patient, April 2018

1.18. Ureteroscope became stuck within the ureter of the patient during withdrawal of the device, April 2018

1.19. During an unspecified Ureteroscopy procedure, the tip of the scope broke off into pieces inside the patient, April 2018

1.20. During the reprocessing process of the Ureteroscope, the bending section was found with a broken rib/skeleton protruding through the bending section, April 2018

1.21. During an unspecified procedure, the Ureteroscope bending section broke, April 2018

1.22. During the reprocessing of the Ureteroscope, the bending section skeleton rib was found broken and punctured a hole on the bending section rubber, April 2018

1.23. Patient suffered trauma to the left vocal cord, suffered submucosal hemorrhages, April 2018

1.24. Failures with dry and wet leak test when the distal cap and distal body failed seal integrity with a deformed biopsy insulation ring on the Duodenoscope, April 2018

1.25. Failure to form a seal between the distal body and distal cap of the Duodenoscope, April 2018

1.26. Failure to form a seal between the distal body and distal cap of the Duodenoscope, April 2018

1.27. A Duodenoscope tested positive for multi-drug resistance pseudomonas during a routine surveillance culturing conducted by the user facility, April 2018

1.28. Object pushed out of Olympus Gastroscope by tech in room, April 2018

1.29. An unspecified Olympus 160 model endoscope was found leaking on the control buttons during an unspecified procedure, April 2018

1.30. During an endoscopic procedure, a part of the distal end of the Olympus ligating device broke and lodged inside the endoscope, April 2018
1.31. Two patients’ digestive tract mucosa turned white after contact with the insertion tube during an unspecified Endoscopy, April 2018

1.32. Two patients’ digestive tract mucosa changed color to white after contact by the insertion portion of the Colonovideoscope, April 2018

1.33. The user facility found that the bending section of the Ureteroscope broke during a therapeutic procedure, March 2018

1.34. An unspecified number of patients Bronchoalveolar Lavage (BAL) washings tested positive for mycobacterium porcinum, March 2018

1.35. An unspecified number of patients Bronchoalveolar Lavage (BAL) washings tested involving three different Olympus Bronchoscopes, March 2018

1.36. Post procedure, Patient was admitted to the ICU after a Cystoscopy was performed, March 2018

1.37. Debris on distal lens and distal tip of the Cystoscope, patient’s urine tested positive for pseudomonas aeruginosa infection, March 2018

1.38. A blue banding device from the previous case dislodged from the biopsy channel, March 2018

1.39. Patient was perforated during a diagnostic Colonoscopy procedure, February 2018

1.40. Patient had undergone a diagnostic upper endoscopy with a Gastrointestinal Videoscope, felt pain in the left breast and back, February 2018

1.41. A pancreatic stent was pulled out of a Duodenoscope with tweezers during the cleaning process after an ERCP procedure was performed, December 2017

1.42. Pentax Medical became aware of a cleaning issue and several malfunctions on the Duodenoscope ED-3490TK, November 2017

2. Failures Due to Reprocessing Equipment (AERs)......................Pages 26-30

2.1. Unknown yellow residue was found in the basin and drain screens of a user facilities AERs, July 2018

2.2. A Duodenoscope has tested positive for bacteria during repeated culturing tests at the user facility, July 2018

2.3. AER caught fire during reprocessing, May 2018

2.4. Customer incorrectly installed their Medivors CER-2 Optima AER, resulting in HLD being pulled through the machine, May 2018
2.5. **There was a burning odor emitting from the AER light socket and a small flame coming from the light socket,** May 2018

2.6. **Blue residue remaining in Endoscopes and hookup tubing after reprocessing in the Advantage Plus Automated Endoscope Reprocessors,** April 2018

2.7. **During a yearly in-service with Medivators clinical education specialist reported the facility was using the incorrect hookups for endoscopes,** March 2018

2.8. **Facilities experiencing a white residue being left on Olympus endoscopes after reprocessing in AERs,** March 2018

2.9. **SD-201 Automated Endoscope Reprocessor was programmed with the incorrect number of rinses required for HLD,** December 2017

3. **Water Quality Issues**

3.1. **Olympus was Informed Several Bronchoscopes Model #s BF-260, BF-1T260, and BF-F260 Tested Positive for Fungus as a result of Microbiological Culturing Testing by the Facility,** March 2018

4. **Use Errors**

4.1. **A Bronchoscope was reported to have seven positive cultures following seven Bronchoscopy procedures on seven patients,** August 2018

4.2. **A Gastrointestinal Videoscope tested positive for unspecified drug-resistant bacteria after being reprocessed twice,** August 2018

4.3. **User Facility is unsure whether a patient had an existing infection with Klebsiella pneumoniae Carbapenemase or Duodenoscope was the cause of the infection,** July 2018

4.4. **One of three scopes cultured positive after reprocessing three different times,** July 2018

4.5. **An employee experienced a burning sensation while unloading instruments that were processed in a V-Pro Max sterilizer,** June 2018

4.6. **A Gastrointestinal Videoscope test positive during a surveillance culturing test at the facility,** June 2018

4.7. **A Duodenscope tested positive for Escherichia coli, Coagulase negative staphylococcus and Bacillus,** June 2018

4.8. **A Pentax Duodenoscope cultured positive after sampling was performed and yielded a total of 187 CFU,** June 2018
4.9. **A foreign body of “biological appearance” was expelled through the distal end of the instrument channel of the Colonovideoscope, June 2018**

4.10. **During a routine culturing test conducted on March 12, 2018, the Colonovideoscope tested positive for bacteria, May 2018**

4.11. **A Colonovideoscope tested positive after multiple microbiological testing by the user facility, May 2018**

4.12. **During a Polyectomy, fine dark grey graphite powder leaked out from the Colonovideoscope, May 2018**

4.13. **Olympus sent device testing positive for Micrococcaceae to a third-party laboratory after repeated test were performed, May 2018**

4.14. **A Cystonephrofiberscope tested positive for Staphylococcus aureus after microbiological testing, May 2018**

4.15. **Gastrointestinal Videoscope tested positive during a surveillance culturing test by the facility, April 2018**

4.16. **Multiple testing by the user facility, microbes were detected from sample collected, April 2018**

4.17. **Patient experiencing fever and chills post procedure went to the ER after a Ureteroscopy and stent placement, April 2018**

4.18. **The user facility conducted a microbiological test on the suction channel of a Colonovideoscope, April 2018**

4.19. **Guidewire and a laser probe could not pass through the instrument channel of the Ureteroscope, February 2018**

4.20. **Baystate Medical Center warns patients after unclean Colonoscope discovered Massachusetts, January 2018**

4.21. **Twenty-Three patients Test Positive for Mycobacterium chelonae from Bronchoalveolar lavage samples, January 2018**

4.22. **Nine patients tested positive for mold spores after undergoing unspecified Bronchoscope procedures, January 2018**

4.23. **Samples show that Mycobacterium Tuberculosis grew from two patients after a bronchoscopy procedure, January 2018**

4.24. **Three patients infected with the association of two contaminated Bronchoscopes, January 2018**

4.25. **The distal end of the Uretero-Reno Videoscope broke inside the patient and caused injury to the patient, January 2018**

4.26. **Guidewire coating chipped away during procedure while using a Ureteroscope, January 2018**

4.27. **Three times cultures were found on a Colonoscope that was conducted by the user facility, January 2018**
4.28. **Endoscope Reprocessing Technician experienced chemical exposure symptoms after handling an endoscope**, January 2018

4.29. **Blue residual fluid dripping from Olympus Endoscopes while hanging in a storage closet**, January 2018

4.30. **Facility reported a waxy green substance in the basin of their Advantage Plus AER**, January 2018

4.31. **Five patients that acquired infections from a contaminated Fiber Bronchoscope**, December 2017

5. **Gram Negative Bacteria Outbreak** ............................................................ Pages 45-58

5.1. **Patient tested positive for Enterococcus casseliflavis infection after undergoing an ERCP procedure**, July 2018

5.2. **Carbapenem-resistant Enterobacteriaceae outbreak with multiple patients infected and reported to Olympus**, May 2018

5.3. **Samples Were Taken from Ten Patients that were growing Pseudomonas Aeruginosa, Serratia Marcescens**, April 2018

5.4. **Foreign material was found present in a Colonoscope during a diagnostic Colonoscopy**, December 2017

5.5. **Four Patients Tested Positive for Drug-resistant Klebsiella pneumonia After Having Undergone ERCP**, October 2017

5.6. **An Olympus Colonovideoscope Linked to Salmonella zanzibar Infection**, October 2017


5.8. **Carbapenem-Resistant Klebsiella pneumoniae Cluster Associated with Gastroscope Exposure among Surgical Intensive Care Unit Patients at University of Pittsburgh Medical Center, Pennsylvania**, October 2016

5.9. **Nurse claims University of Cincinnati Health failed to stop infectious outbreak**, Ohio, June 2016

5.10. **CRE death linked to ERCP procedure at Lehigh Valley hospitals**, Pennsylvania, April 2016

5.11. **Multidrug-Resistant E. coli Infects Patients at University of Colorado Hospital, Colorado**, January 2016


5.13. **Psuedomonas outbreak at Huntington Hospital in Pasadena, California**, August 2015


5.15. **CRE Outbreak at Cedars-Sinai in Los Angeles**, California, March 2015


5.17. **CRE Outbreak at University of California, Los Angeles (UCLA)**, California, January 2015
5.18. A Genetic and Epidemiological Analysis of Antibiotic-Resistant Enterobacteria Identifies an Endoscope as the Possible Source of an Outbreak, France, 2012-2014

5.19. CRE Outbreak at Seattle Hospital, Washington, 2012-2014

5.20. CRE Outbreak at Lutheran General Hospital in Park Ridge, Illinois, December 2013

5.21. Outbreak of Hospital Infection from Biofilm-embedded Pan Drug-resistant *Pseudomonas aeruginosa*, Due to a Contaminated Bronchoscope, Turkey, October 2013

5.22. Gram-Negative Pneumonia Death Linked to Contaminated Scope, Washington, February 2013

5.23. CRE Outbreak at University of Pittsburgh Medical Center, Pennsylvania, November 2012

5.24. CRE Outbreak National Institute of Health (NIH), Maryland, June 2011

5.25. Emergence of Glutaraldehyde-Resistant *Pseudomonas aeruginosa*, Switzerland, November 2009


5.27. Early Identification and control of carbapenemase-producing *Klebsiella pneumoniae*, originating from contaminated endoscopic equipment, June 2008- January 200


5.30. An outbreak of *Pseudomonas aeruginosa* infections following thoracic surgeries occurring via the contamination of bronchoscopes and an automatic endoscope reprocessor, Japan, May - June 2003

5.31. Unusual implication of biopsy forceps in outbreaks of *Pseudomonas aeruginosa* infections and pseudo-infections related to bronchoscopy, France, January – April 2003

5.32. Multidrug-Resistant *Pseudomonas aeruginosa* Cholangitis after ERCP, Illinois, July 2002


5.34. An outbreak of multidrug-resistant *Pseudomonas aeruginosa* infection associated with contamination of bronchoscopes and an endoscope washer-disinfector, England, October – November 1998

5.35. Nosocomial Transmission of *Pseudomonas aeruginosa* Following Bronchoscopy Associated with Improper Connection to the STERIS SYSTEM 1 Processor, New York, August - October 1998

1. Failure of Visual Inspection

1.1. The angulation of the bending section of the Uretero-Reno Fiberscope did not work in the down direction, July 2018

A report in the FDA MAUDE database states that during percutaneous nephrolithotripsy, the user facility noticed the angulation of the bending section did not work in the down position, that it remained in a U shape. The Uretero-Reno Fiberscope URF-P6 was removed from the patient to inspect it when they felt something wrong with the endoscopic image. There was not a spare device available, so the procedure was abandoned. The Fiberscope was brand new. The device was sent to OMSC for evaluation, the section kept angulation for the down direction without operation of the up/down angulation control lever. There was also a leak from the instrument channel with many scratches inside of the instrument channel. There was no irregularity when OMSC reviewed the manufacturer history of the Fiberscope.


1.2. An employee received a burn on their hand while unloading instruments from their V-Pro Max, June 2018

A report in the FDA’s MAUDE database states that at a user facility an employee received a burn on their hand while unloading instruments from their V-Pro Max sterilizer. The employee rinsed off their hand with water and returned to work. A Steris service technician arrived onsite and found the sv4 (injection valve) and sv5 (reservoir valve) did require replacement, causing the instrument packs to not fully dry. The sc4 and sc5 were replaced and ran a test cycle, the unit is operation according to specifications and returned it to service. The Steris technician confirmed the employee was not wearing PPE specifically chemical resistant gloves while removing the instruments. The Steris account manager provided a full in-service training on the proper use and operation of the V-Pro Max sterilizer and wearing appropriate PPE.

1.3. A V-Pro Max sterilizer was found to be emitting a mist that filled the room with “haze”, May 2018

A report in the FDA’s MAUDE database states that a V-Pro Max sterilizer was found to be emitting a mist that filled the room with “haze” activating the facility’s fire alarm. The Steris service technician arrived at the facility to inspect the sterilizer and observed that the oil filters were saturated with oil and oil residue. The vacuum pump oil is non-toxic and not considered hazardous. The valves and filters were replaced and ran a test cycle and found the unit to operating according to specifications. The unit was returned to service with no additional issues.


1.4. The bending section of the Uretero-Reno Fiberscope broke inside the patient with a non-Olympus laser probe inserted into the channel of the Fiberscope, May 2018

A report in the FDA’s MAUDE database states during and RIRS (retro intrarenal surgery) procedure the bending section of the Fiberscope URF-P6 broke off inside the patient. The Fiberscope was safely removed from the patient, but a part of the laser fell off into the patient. The user facility performed an open surgery in order to retrieve the part of the laser from the patient. There was no complication and the patient is doing well. The Fiberscope was delivered to the facility in 2018. The exact cause of the event could not be conclusively determined at this time.


1.5. The shaft of a LithoVue scope used in a Ureteroscopy procedure bent over onto itself and locked during the procedure, May 2018

A report in the FDA’s MAUDE database states that a single use Digital Flexible Ureteroscope M0067913600 shaft of the LithoVue scope bent over onto itself and locked during the a Ureteroscopy procedure while inside the patient. The scope was not constrained in the patient’s anatomy and the shaft could not be straighten when articulating, a super stiff wire was used to manipulate the shaft and the scope was removed from the patient. The deflection mechanism works fine when not inside the patient. Another LithoVue scope was used to complete the procedure with no complications to the patient. The scope was disposed and will not be returned for evaluation and a failure analysis of the device could not be completed.
1.6. Pentax Duodenoscope failed a cleaning verification test three times using 3M Clean Trace and sent to Pentax were several areas of scope had wear and tear, May 2018

A report in the FDA’s MAUDE database states Pentax Video Duodenoscope ED-349TK failed a cleaning verification test three times using the 3M Clean Trace at the elevator site to detect ATP/Bioburden. First tech, tested and failed, rewrashes and tested by a second tech and failed, third time a third tech cleans the scope and retests. The scope was sent in for inspection of integrity and possible repair. The user facility stated endoscopes are cleaned in accordance with Pentax instructions for use and test after every use. Pentax findings include the following: primary operation channel resistance, hole in #1 and #3 remote control button cover, bending rubber, severe discoloration. The scope passed the dry/wet leak tests. The objective lens scratched. Umbilical cable was bent, elevator body cut and deformed, light carrying bundle, distal cover glass middle chipped, the insertion tube mild crush at stage 1, distal cap-fix typed failed seal integrity inspection. The Duodenoscope is currently undergoing repairs.

1.7. During an unspecified transnasal bronchoscopy, the rhinal mucosa of the patient was injured with a small amount of bleeding, May 2018

A report in the FDA’s MAUDE database states that the patient was injured with a small amount of bleeding and treated by astriction using gauze. The device was sent to Olympus Sales & Service Co., LTD. for evaluation and confirmed a projection on the bending section rubber of the device and an air leakage around the projection. The bending section rubber was disassembled and confirmed that several metal filaments of the inner parts of the bending section rubber frayed and broke at the leakage point. OCM reviewed the service history of the device the insertion portion of the Bronchoscope BF-1T260 was replaced due to an air leakage from the instrument channel, scratches on the insertion portion, and wear and tear of the insertion portion. Also, the bending section rubber was replaced due to the leakage from the bending section rubber. The exact cause could not be determined at present.
1.8. During an unspecified procedure, a wire was found sticking out of the insertion tube, May 2018

The Ureteroscope URF-V2R was returned to Olympus for evaluation after an unspecified procedure a wire was found sticking out of the insertion tube. Olympus performed a visual inspection on the scope and found the bending section skeleton completely broken/detached with damages found on the angle wires, the biopsy channel, and the charge couple device unit. Upon removing of the bending section cover, one side of the angle wires was found broken with a sharp surface noted. The exposed biopsy channel was found kinked from the bending section area of the scope. Olympus was unable to perform leak testing due to the condition of the scope. The Ureteroscope was serviced and returned to the user facility. There was no patient injury reported.


1.9. A rubber piece from Ureteroscope fell off inside the patient’s ureter at the beginning of a kidney stone procedure, May 2018

A report in the FDA’s MAUDE database states at the beginning of a kidney stone procedure, a rubber piece from the scope fell off inside the patient’s ureter. The rubber piece was retrieved, and the procedure was completed using the same Ureteroscope URF-V. It was further reported the device was inspected during reprocessing, prior to the procedure, and no anomalies were found. The scope was returned to Olympus for evaluation and a visual inspection was performed on the scope and found the bending section cover glue was broken off and missing from the distal end side and insertion tube side. The missing portion of the glue on both the distal end and insertion tube of the scope were not returned to Olympus. Due to the missing glue, the thread assembly from the bending section was found exposed. The scope failed leak testing as a result to the damages on the bending section cover glue. The Ureteroscope was serviced and returned to the user facility. User handling and improper maintenance of the scope could not be ruled out as contributing factors to the reported event. There was no patient injury reported.

https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfMAUDE/detail.cfm?mdrfoi__id=7520909&pc=GB
1.10. During the reprocessing of the Ureteroscope, the distal tip was noted to have sharp edges and was found broken, May 2018

A report in the FDA’s MAUDE database states Olympus was informed that during the reprocessing of the Ureteroscope URF-V2R, the distal tip was noted to have sharp edges and was found broken. Olympus made multiple follow ups with the user facility by telephone and in writing in an attempt to gather further information on the reported event. No additional information was obtained. The Ureteroscope was returned to Olympus for evaluation and confirmed the reported device issue. The bending section was found damaged/torn with the metal ribs exposed. In addition, the bending section rubber glue was found with a hole/cut and in critical condition causing the scope to fail leak testing. The scope was serviced and returned to the user facility. Based on similar reported events and performed investigation findings, the cause of the reported device issue could be attributed to the operator(s) technique. The OEM has conducted a field corrective action including a distribution of instructions for safe use to mitigate the potential risk of patient injury. There was no patient injury reported.


1.11. Multiple microbiological testing by the user facility, following microbes were detected from a Bronchovideoscope BF-1T180, May 2018

A report in the FDA’s MAUDE database states the instrument channel of the Bronchovideoscope BF-1T180 tested for unspecified microbes >300cfu/20ml. The air/water channel of the scope tested for unspecified microbes >300cfu/20ml, the instrument channel of the scope tested for >300cfu and unspecified microbes >300cfu. No report of infection associated with this report. The Bronchovideoscope was not returned to Olympus medical systems corp. and reviewed the manufacturing history of the subject device and confirmed no irregularity. The exact cause of the reported event could not be conclusively determined at this time.


1.12. An unspecified number of patient infections occurred at a user facility with the use of Olympus Cystoscopes during an unspecified number of procedures, May 2018

A report in the FDA’s MAUDE database states the types of infections are unknown and the exact model and serial number of the Cystoscope that caused or contributed to patient infections are also
unknown. A total of three Cystoscopes are in use at the user facility. Olympus was informed and made multiple follow ups with the user facility by telephone and in writing in an attempt to gather information on the reported event. The Cystoscope CYF-V2 has not been returned to Olympus for evaluation. A review of the scope history was performed and found that the scope was purchased on November 30, 2010 and last serviced at Olympus on August 30, 2016 for a bending section issue. The scope was returned un repaired. An ESS provided a routine reprocessing in-service and found that the user facility does not have a leak tester and are not leak testing the scopes and not using detergent. The staff was using reusable brushes and not sterilizing in between uses. Recommendation were made by the ESS to purchase a leak tester, detergent, to sterilize the reusable brushes or purchase single use brushes. The ESS also recommended switching from Cidex OPA to Aldahol. The user facility declined from purchasing a leak tester but did however purchase Aldahol and were returned. On May 10, 2018 the ESS returned to the user facility to follow up on initial recommendations and found that the user facility is now sterilizing their reusable brushes and following correct cleaning and disinfection process. The ESS found that the reprocessing area is also located in the same room where procedures take place. In addition, the scopes are stored in a different procedure room and not in an enclosed ventilated cabinet. The ESS recommended to staff to follow the reprocessing protocol as stated in the instruction manual and to also consult with an infection control preventionist and have a designated separate room as their reprocessing area to prevent cross contamination. The user facility declined a reprocessing in-service during this visit. Based on the ESS findings, most likely the cause for the infections is likely related to mis-reprocessing and improper maintenance of the scope. Olympus was informed on May 10, 2018 that there were three pseudomonas infections and a potential urinary tract infection uti/pid. Olympus is filing three reports to account for the three infected patients and reported Cystoscopes.


**1.13. An unspecified number of patient infections occurred at a user facility with the use of Olympus Cystoscopes during an unspecified number of procedures**, May 2018

A report in the FDA’s MAUDE database states the types of infections are unknown and the exact model and serial number of the cystoscope that caused or contributed to the patient infections are also unknown. A total of three Cystoscopes are in use at the user facility. Olympus was informed and made multiple follow ups with the user facility by telephone and in writing in an attempt to gather information on the reported event. The Cystoscope CYF-VH has not been returned to Olympus for evaluation. During the investigation, a review of the device service history was performed and found no service information on the reported scope. An ESS provided a routine in-service at the user facility on January 18, 2018 to observe the facility’s reprocessing practice and to provide a reprocessing
training. ESS found the user facility did not have a leak tester and was not leak testing as stated in the
instruction manual as well as not using detergent. A recommendation to purchase a leak tester and
detergent, to sterilize their reusable brushes or purchase single use brushes, switch from Cidex OPA to
Aldahol as Cidex is not recommended for sure. Facility declined to purchase a leak test but did
purchase Aldahol and were returned. The ESS returned to the user facility for a follow up and found
the user facility is now sterilizing their reusable brushes and following the reprocessing protocol as
stated in the instruction manual. A recommendation was made to the user facility to consult with an
infection control preventionist and have a designated separate room as their reprocessing area to
prevent cross contamination. The user facility declined a reprocessing in-service during this visit.
Based on the ESS findings, most likely the cause for the patient infections is likely related to
misreprocessing and improper maintenance of the scope. Olympus was informed that there were
three pseudomonas infections and a potential urinary tract infection uti/pid. The urinary tract
infection incident has not been confirmed. Olympus is filing three reports to account for the three
infected patients and reported Cystoscopes.


1.14. Several patients became infected after ERCP procedure with the same Duodenoscope, May
2018

A report in the FDA’s MAUDE database states that several patients have been exposed to the same
Duodenoscope ED-3490TK in 2018. Patient B underwent and Endoscopic Retrograde Cholangio-
Pancreatography for primary sclerosing cholangitis with a Pentax Duodenoscope. Patient B returned to
the emergency room two day later with right upper quadrant pain, body aches, shaking chills and fever
of 101.8. Six days post initial ERCP, the patient underwent another ERCP; a bile duct aspirate grew out
multi-drug resistant Pseudomonas aeruginosa, which patient B had not prior history of this organism.
Infection control was alerted to patient B by the infectious disease consult physician seeing the patient
fourteen-day post initial ERCP. Patient A was identified by the infection control unit investigation had
undergone an ERCP in early 2018 with the same scope who was known to carry a MDR PSA prior to the
procedure. Patient C had an ERCP in mid-2018 with the Pentax Duodenoscope developed bacteremia
with MDR PSA with no know history. To determine if the infections were similar, the Pseudomonas
isolates where sent out for genomic analysis including multilocus sequence typing and whole genome
sequencing in mid-2018. Seven days post testing, preliminary results demonstrated the isolates from
patients b and c were highly related to patient a. In mid-2018 an additional patient D underwent ERCP
with the same scope was found to have a positive bile culture for PSA in early 2018. Both MDR PSAs
from patient D have the same antibiogram as patient A. The Pentax Duodenoscope was sequestered
and taken out of service pending further investigation near the end of 2018.
1.15. *The lens of an ERCP Duodenoscope was discovered to be green*, May 2018

A report in the FDA’s MAUDE database states that the facility cleaning and drying according to the manufacturer’s instructions discovered the lens of an ERCP Duodenoscope TJF-Q180V was green. Six of twenty-two lenses were found green and two of the six had distorted images and were sent out for repair. An Olympus field rep. responded to the facility that the green discoloration around the lens of the scope on the glue used by the scope manufacturer for securement. The scope was changed out for one without lens discoloration.

1.16. *A customer reported an event of a strong odor emitting from the Sterrad® 100NX Sterilizer after the cycle completes*, May 2018

A report in the FDA’s MAUDE database states a customer reported an event of a strong odor emitting from the Sterrad® 100NX Sterilizer after the cycle completes, and the chamber door is opened. A healthcare worker experienced burning in both eyes but did not seek or receive any medical attention because the pain subsided once they left the room. It was advised to turn off the machine and leave the room. Based on information received, the healthcare workers symptoms suggest the event was not serious and resolved without medical attention. A field service engineer was dispatched to the customer site and the vacuum pump and vacuum pump control were replaced to resolve the odor/smell issue.

1.17. *A Cystonephrofiberscope was noted as having approximately 3cm of its covering missing as it was being removed from the patient*, April 2018

A report in the FDA’s MAUDE database states that Olympus was informed by the facility that at the end of a second stage Buccal Urethroplasty with suprapubic placement procedure using a Cystonephrofiberscope CYF-5 was missing approximately 3cm of its covering as it was being removed from the patient and exposing the metal mesh of the scope. The missing piece was retrieved, and all
parts accounted for, the procedure was completed using the same scope. Prior to use, the scope was inspected with no anomalies were found by Olympus. The scope was cleaned using Steris and with the concentration check daily with each load in the Olympus AER with no noted problems. Precleaning is performed after each procedure and leak checked prior the manual cleaning with an Olympus leak tester and a brush is using during manual cleaning with an Olympus single use brush. The scope is sterilized Sterrad® in an Aptimax tray and stored until use. All personnel are properly trained. No service information was found for this scope and was not returned to Olympus for evaluation. User handling and the operator(s) technique during use could not be ruled out as a contributing factor.


1.18. **Ureteroscope became stuck within the ureter of the patient during withdrawal of the device**, April 2018

A report in the FDA’s MAUDE database states Olympus was informed that the Ureteroscope URF-P5 became stuck with the ureter of the patient during withdrawing the scope with a ureteral access sheath at the end of the transurethral lithotripsy. The access sheath could be withdrawn but the device could not. The user facility tried to withdraw the device under x-ray fluoroscopic image. A part of the ureter was retrieved and withdrawn with the subject device. The facility immediately changed the procedure into a laparotomy surgery to repair the ureter and completed the procedure. The patient’s hospitalization was prolonged.


1.19. **During an unspecified Ureteroscopy procedure, the tip of the scope broke off into pieces inside the patient**, April 2018

A report in the FDA’s MAUDE database Olympus was informed that during an unspecified ureteroscopy procedure, the tip of the scope broke off into pieces inside the patient. It was reported that a Holium laser was used with the Ureteroscope URF-P5 during the procedure. The physician was unable to retrieve all of the device fragments from the patient and will be scheduling another endoscopic procedure to retrieve the remaining device fragments. Olympus made multiple follow ups with the user facility to telephone and in writing in an attempt to gather additional information on the reported event. No additional information was obtained. The user facility further reported that the reported scope will be sent to a non-Olympus third party entity for evaluation and service. The device
service history was performed and found that the scope was purchased in 2018 and was never returned to Olympus for evaluation. The cause of the reported device based on similar reported events is that it is likely related to the operator technique.


1.20. During the reprocessing process of the Ureteroscope, the bending section was found with a broken rib/skeleton protruding through the bending section, April 2018

A report in the FDA’s MAUDE database states that during the reprocessing process of the Ureteroscope URF-V2R, the bending section was found with a broken rib/skeleton protruding through the bending section rubber. No patient/user injury reported. Olympus performed a visual inspection and found a portion of the bending section with a sharp edge and exposed/protruding bending skeleton metal tab causing the scope to fail leak testing. Upon the removal of the bending section cover, the bending section skeleton was found completely broken/detached with a sharp edge. The cause of the protruding/lifting skeleton metal tab could be attributed to the operator(s) technique. The original equipment manufacturer (OEM) has conducted a field corrective action including a distribution of instruction for safe use to mitigate the potential risk of patient injury.


1.21. During an unspecified procedure, the Ureteroscope bending section broke, April 2018

A report in the FDA’s MAUDE database states the bending section cover was found with a hole/cut and the bending section skeleton ribs were found broken. The scope was returned to Olympus and an evaluation found the bending section in critical condition. Based on similar reported events and investigation findings, the cause of the protruding/lifting skeleton metal tab could be attributed to the operator(s) technique. The original equipment manufacturer (OEM) performed investigations related to this device issue. As a result, the OEM has conducted a field corrective action including a distribution of instruction for safe use to mitigate the potential risk of patient injury.

1.22. During the reprocessing of the Ureteroscope, the bending section skeleton rib was found broken and punctured a hole on the bending section rubber, April 2018

A report in the FDA’s MAUDE database states that the Ureteroscope URF-V2R was returned to Olympus for evaluation and performed a visual inspection and found the bending section skeleton broken causing an abnormal movement with he up and down angulation. A cut was found on the bending section cover where the broken bending section skeleton is located. Upon removing the bending section cover, the bending section skeleton metal tab was found broken/detached. The scope was serviced and returned to the user facility. Based on similar reported events and investigation findings, the cause of the protruding/lifting skeleton metal tab could be attributed to the operator(s) technique. There was no patient injury reported.


1.23. Patient suffered trauma to the left vocal cord, suffered submucosal hemorrhages, April 2018

A report in FDA’S MAUDE database states Olympus was informed that during a bronchoscopy left upper lobe lavage procedure, the patient suffered trauma to the left vocal cord, suffered submucosal hemorrhages, and experienced a sore throat post procedure as the bronchoscope did not advance in the trachea and into the patient as it was stuck in a retroflexed position and took 20 minutes for the Bronchoscope BF-H190 to gently extend into a neutral position. It was also reported that upon inspection of the scope post procedure an indentation mark/kink about 2 inches from the distal tip of the scope was found. The physician did not notice the kink prior to the procedure. Olympus made multiple follow ups with the user facility by telephone and in writing in an attempt to gather additional information on the reported event. The scope was not returned to Olympus for evaluation. Olympus performed a device service history review and found that the scope was purchased in 2014 and was lasted serviced at Olympus in 2017. Based on similar reported events, improper maintenance of the device could not be ruled out as a contributing factor to the reported event.


1.24. Failures with dry and wet leak test when the distal cap and distal body failed seal integrity with a deformed biopsy insulation ring on the Duodenoscope, April 2018

A report in the FDA’s MAUDE database states Pentax of America initiated field correction 2017-001-c which included inspection of the seal around the distal body and distal cap of the Duodenoscope ED-
3490TK pursuant to predefined inspection criteria. The inspection was to verify there were no defects/discontinuities in the seal between the distal body and distal cap. The customer owned device was previously returned to Pentax medical from a customer on April 13, 2018 with a concern of fail dry leak test. On April 16, 2018 an inspection was performed where the quality control inspector found a bending rubber pinhole, prism scratched, distal cap/case cracked, biopsy insulation ring deformed, failed wet leak test, segment steel braid twisted, failed dry leak test, distal cap-fixed type failed seal integrity inspection. The device is currently in the repair process.


1.25. Failure to form a seal between the distal body and distal cap of the Duodenoscope, April 2018

A report in the FDA’s MAUDE database states Pentax of America initiated field correction 2017-001-c which included inspection of the seal around the distal body and distal cap of the Duodenoscope ED-3490TK pursuant to predefined inspection criteria. The inspection was to verify there were no defects/discontinuities in the seal between the distal body and distal cap. The customer owned device was previously returned to Pentax medical from a customer on April 9, 2018 with a complaint of bending rubber tear at distal end. On April 10, 2018 an inspection was performed where the inspector found failures: bending rubber pinhole, prism scratched, distal cap, fixed typed failed seal integrity inspection, image shadows, failed dry/wet leak test, lightguide prong scratched, customer complaint confirmed, umbilical cable bump under pve root brace, bending rubber leak at middle section, lightguide prong glass set scratched. The scope is currently pending repair.


1.26. Failure to form a seal between the distal body and distal cap of the Duodenoscope, April 2018

A report in the FDA’s MAUDE database states Pentax of America field correction which included inspection of the seal around the distal body and distal cap of the Duodenoscope ED-3490TK pursuant to predefined inspection criteria. The inspection was to verify there were no defects/discontinuities in the seal between the distal body and distal cap. The customer owned device was previously returned to Pentax medical from a customer in 2018 and inspected on order where the inspector found the following failures: distal cap fixed type failed seal integrity inspection, air/water socket cylinder o-ring chipped, prism scratched, passed dry/wet leak test, distal cap/case chipped, ETO vent valve loose inner shaft, middle light carrying bundle distal cover glass cracked, elevator body screw loose. Operation
1.27. **A Duodenoscope tested positive for multi-drug resistance pseudomonas during a routine surveillance culturing conducted by the user facility**, April 2018

A report in the FDA’s MAUDE database states that during a routine surveillance culturing conducted by the user facility, the Duodenoscope TJF-Q180V was test positive for multi-drug resistant Pseudomonas (1cfu/100ml). The scope used on the patient who was a known Pseudomonas carrier. The scope was used on two patients which the user facility identified on one of two patients the same Pseudomonas strain as on the carrier patient. The Duodenoscope had been reprocessed using Soluscope 4, a non-Olympus AER model. Visual inspection confirmed the following; chips and scratches on the adhesive of the bending section and adhesives discolored to gray. There were dents and scratches on the distal end cover, wear and tear, brown parts, cracks and two pinholes on the adhesive of the distal end. The adhesive color was gray, cracks and missing part on the adhesive around the air/water nozzle and adhesive was gray in color. There were cracks inside of the light guide lens, pinholes on the adhesive around the objective lens and light guide lens and were peeled off. Annual inspection was conducted on the scope in 2017 and minor repair was conducted in 2017.


1.28. **Object pushed out of Olympus GastroScope by tech in room**, April 2018

A report in the FDA’s MAUDE database states that an Olympus GIF-H180 seemed clogged. The tech in the room did a backflush of the scope after the case and was being cleaned pushed out an object. The object was given to the endoscopy supervisor.

1.29. An unspecified Olympus 160 model endoscope was found leaking on the control buttons during an unspecified procedure, April 2018

A report in the FDA’s MAUDE database states an unspecified Olympus 160 model endoscope was found leaking on the control button during an unspecified procedure and the patient contracted a stomach infection. It is unknown if the leaking scope is what caused the infection in the patient or the reprocessing of the scope. A different scope was used to finish the procedure. Olympus made multiple follow ups with the user facility by telephone and in writing in an attempt to gather more information on the reported event. Since not model or serial number was provided, Olympus was unable to perform a device service history review. It could be conclusively determined the cause of the reported patient infection.


1.30. During an endoscopic procedure, a part of the distal end of the Olympus ligating device broke and lodged inside the endoscope, April 2018

A report in the FDA’s MAUDE database states the Olympus was informed that during an unknown procedure involving an unknown make and model endoscope, a part of the distal end of the Olympus ligating device broke and lodged inside the endoscope. The endoscope was reprocessed using an unknown process and third-party brush made by US Endoscopy. A second procedure was done with the same endoscope which the broken off piece of Olympus ligating device was pushed in the second patient and the broken piece was retrieved with no further reported incident or adverse event.


1.31. Two patients’ digestive tract mucosa turned white after contact with the insertion tube during an unspecified Endoscopy, April 2018

A report in the FDA’s MAUDE database states that during two unspecified Endoscopy, the facility noticed the digestive tract mucosa of two patients changed their colors into white after contacted by the insertion tube of the Colonovideoscope CF-Q180AI. The facility thought the events were due to a rinsing problem (insufficient rinse during reprocessing) since the facility manually disinfected the scope with peracetic acid. The scope was not returned to Olympus Medical Systems Corp. and the exact cause could not be determined at present.
1.32. Two patients’ digestive tract mucosa changed color to white after contact by the insertion portion of the Colonovideoscope, April 2018

A report in the FDA’s MAUDE database states during an unspecified Endoscopy, two patients’ digestive tract mucosa changed color to white after contact by the insertion portion of the Colonovideoscope CF-Q180AI. The events were due to a rinsing problem (insufficient rinse during the reprocessing). The facility had manually disinfected the scope with peracetic acid. The facility followed up the patients by phone after the procedure and confirmed they are doing fine. The scope has not been returned to Olympus Medical System Corp.

1.33. The user facility found that the bending section of the Ureteroscope broke during a therapeutic procedure, March 2018

A report in the FDA’s MAUDE database states the Ureteroscope URF-V2 was returned to OMSC for evaluation and confirmed that air leak from the bending section of the device and the metal part was exposed from the bending section rubber. The OMSC also confirmed no irregularity. The exact cause of the reported event could not be conclusively determined at this time as the evaluation has not been completed.

1.34. An unspecified number of patients Bronchoalveolar Lavage (BAL) washings tested positive for mycobacterium porcinum, March 2018

A report in the FDA’s MAUDE database states Olympus was informed by the user facility that an unspecified number of patients bronchoalveolar lavage (BAL) washings tested positive for Mycobacterium porcinum involving three different Olympus Bronchoscopes. Further reports states that the scopes were not cultured. The scopes are precleaned after each procedure in the OR and manually cleaned and channels of the scopes are brushed with a non-Olympus Halyard single use dual-ended cleaning brush, leak tested with an Olympus leak tester, then processed in a non-Olympus Steris
1e AER machine. The last preventative maintenance on the AER machine was March 20, 2018 with no problems reported. The scopes are hung in a ventilated scope cabinet. The patients are fine and have been discharged. The Bronchovideoscope BF-H190 was returned to Olympus for evaluation and is still in progress and pending results. The scopes will be sent to an independent lab for microbial testing and ETO sterilization. An Endoscopy support specialist (ESS) was requested to be dispatched to the user facility to observe the facility’s reprocessing practice and to provide a reprocessing training. The ess visit has not been finalized.


1.35. An unspecified number of patients Bronchoalveolar Lavage (BAL) washings tested involving three different Olympus Bronchoscopes, March 2018

A report in the FDA’s MAUDE database states Olympus was informed by the user facility that an unspecified number of patients Bronchoalveolar Lavage (BAL) washings tested for involving three different Olympus Bronchoscopes BF-H190. It was reported that the scope was not cultured. The scopes are pre-cleaned after each procedure in the OR and manually cleaned and the channels of the scopes are brushed using a non-Olympus Halyard single use dual-ended cleaning brush. The scopes are leak tested using an Olympus leak tester and reprocessed in a non-Olympus Steris 1E AER machine. The scopes are hung in a ventilated scope cabinet. The scope was returned to Olympus for evaluation and is still in progress and pending results. The scopes will be sent to an independent lab for microbial testing and ETO sterilization. An Olympus endoscopy specialist (ESS) was requested to be dispatched to the user facility to observe the facility’s reprocessing practice and provide training.


1.36. Post procedure, Patient was admitted to the ICU after a Cystoscopy was performed, March 2018

A report in the FDA’s MAUDE database states the physician performed a Cystoscopy procedure on patient with a 11272NVU Cystoscope. Patient was admitted to the ICU post procedure. Patients urine was cultured and confirmed Pseudomonas aeruginosa infection. Patient was treated by an outside doctor and clinic does not have any information on treatment, patient most likely received antibiotics.

1.37. Debris on distal lens and distal tip of the Cystoscope, patient’s urine tested positive for pseudomonas aeruginosa infection, March 2018

A report in the FDA’s MAUDE database states allegedly, the physician performed a Cystoscopy procedure on patient. Patient’s urine was cultured, and pseudomonas aeruginosa infection was confirmed from the lab results. Patient was given antibiotics by a doctor from an outside clinic, doctor reported patient is doing fine. An evaluation was conducted and concluded there was debris on the distal lens and distal tip, of the Cystoscope 11272VNU, angle cover is cracked and has debris on it as well as the shaft marker rings are discolored. A nick was found on the handle housing. The evaluation suggests the user error can be linked to the physical condition of the instrument.


1.38. A blue banding device from the previous case dislodged from the biopsy channel, March 2108

A report in the FDA’s MAUDE database states that a patient having upper endoscopy, while advancing biopsy forcep down biopsy channel, a blue bending device from previous case dislodged from Gastroscope GIF-H180J. The band was removed.


1.39. Patient was perforated during a diagnostic Colonoscopy procedure, February 2018

A report in the FDA’s MAUDE database states a patient was perforated during a diagnostic Colonoscopy procedure using a Colonovideoscope CF-HQ190L which was found post op. the patient received additional hospitalization and surgery to treat the perforation. The scope was returned to Olympus for evaluation and found the scope bending section discolored. The glue on the bending section was found lifted. There was also deep scratches and indentations on the distal end cover. A review of the scope service history was performed and found it was returned to Olympus multiple times for similar bending section issues. Based on the evaluation results, improper maintenance of the scope could not be ruled out as a contributing factor to the reported event.

1.40. **Patient had undergone a diagnostic upper endoscopy with a Gastrointestinal Videoscope, felt pain in the left breast and back, February 2018**

A report in the FDA’s MAUDE database states that a patient returned to the user facility five hours with pain in the left breast and back after a diagnostic upper Endoscopy with an Evis Lucera Gastrointestinal Videoscope GIF-PQ260. There was possibility that abnormality in the esophageal exterior wall of mediastinum. The patient visited another facility for a CT scan, a perforation of the esophagus was found and was fixed by an endoscopic clipping procedure. It was reported by the user facility that during the insertion of the upper endoscopy procedure, the distal end of the scope was retroflexed and when the facility tried to release the retroflex of the distal end, a laceration occurred in the esophagus at the location of 35 cm from the oral. The procedure continued since there was no bleeding from the laceration the procedure was completed and no bleeding during the withdrawal of the scope. The scope has not been returned to OMSC for evaluation and the exact cause could not be conclusively determined at this time.

[https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfMAUDE/detail.cfm?mdrfoi__id=7556063&pc=FD]{DS}

1.41. **A pancreatic stent was pulled out of a Duodenoscope with tweezers during the cleaning process after an ERCP procedure was performed, December 2017**

A report in the FDA’s MAUDE database states that a pancreatic stent was found in the suction channel of the Duodenoscope ED-3490TK and retrieved with tweezers. The pancreatic stent had not been placed or attempted to be placed in the patient during this procedure or prior procedures. Pentax Medical became aware of a voluntary medwatch adverse event report forwarded by the FDA’s office of surveillance and biometrics. Prior use several weeks earlier, the scope was documented as being cleaned per manufacturers recommendations. Pentax medical followed up with the facility to gather additional details on the event and to obtain the serial number of the Duodenoscope involved. The facility contact stated, that not portion fell into the patient and there was no evidence of patient harm. The scope was returned to the manufacturer and did not find any problems with the scope and it was returned to use.

[https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfMAUDE/detail.cfm?mdrfoi__id=7399329&pc=FD]{DT}

1.42. **Pentax Medical became aware of a cleaning issue and several malfunctions on the Duodenoscope ED-3490TK, November 2017**
A report in the FDA’s MAUDE database states on January 16, 2018, Pentax medical became aware of the identification results of sampling performed on 2017 on Pentax ED-3490TK. The sampling showed a total of 106 CFU of Pseudomonas Aeruginosa, the scope was returned to Pentax on November 14, 2017. When Pentax inspected the scope, the findings included: distal cap- failed seal integrity inspection, hole in and leak at #4 remote control head cover, hole in and leak #2 remote control button cover, air/water socket cylinder o-ring chipped, elevator body, screw loose, failed wet/dry leak test. Repairs were performed and replacement of the biopsy inlet t-piece pb-free, air/water tube, deflector body, deflector body link, deflector operating wire, operation channel, bending rubber, distal cap/case, remote control button (1), deflector body attaching screw, deflector op wire adjusting screw. On January 12, 2018, the Duodenoscope was shipped back to the customer.


2: Failures Due to Automatic Reprocessors (AERs)

2.1. Unknown yellow residue was found in the basin and drain screens of a user facilities AERs, July 2018

A report in the FDA’s MAUDE database states a user facility reported an unknown yellow residue that was found in the basin and drain screens of their Advantage Plus Automated Endoscope Reprocessors with potential patient exposure to the reside during endoscopic procedures. A Medivator engineer did visited the facility to evaluate and clean the units to remove the residue and thoroughly inspect and samples taken for analysis by Medivators R&D. The residue was identified as a silicone-based substance which Medivators technical specialist and FSE confirmed this substance could not be introduced by any component from the AER. The residue was notice for the first time recently after having the AER for about a year and a half. It is unknown how many endoscopes have been reprocessed and if there were changes in the process. The facility is now keeping the drain screens clean and monitoring their units closely. There has been no additional information with the follow up from Medivators.


2.2. A Duodenoscope has tested positive for bacteria during repeated culturing tests at the user facility, July 2018
A report in the FDA’s MAUDE database states that an Evis Exera II Duodenovideoscope TJF-Q180V repeatedly test positive for bacteria during surveillance culturing tests at the user facility. The scope tested positive for Enterobacter cloaceae pseudomonas spp. (>100 cfu/100 ml), Bacillus spp. (24 cfu/100 ml), Sphingomonas paucimobilis (1 cfu/100 ml), Acinetobacter calcoaceticus (1 cfu/100 ml), Acinetobacter species (2 cfu/100 ml) and shigella (2 cfu/100 ml). The scope was also tested positive for gram positive Bacillus (6 cfu/100 ml) and tested positive for unspecified gram-positive bacteria (35 cfu/100 ml). The user facility reprocessed the scope in an Olympus AER ETD-3 and ETD-4. The scope was returned to OMSC and sent to a third-party lab for additional testing which resulted with no microbial growth. It was confirmed that no irregularity was found with the scope. Exact cause could not be determined at present.


2.3. AER caught fire during reprocessing, May 2018

A report in the FDA’s MAUDE database states that a Medivator DSD edge caught fire during reprocessing of an endoscope. No other information was provided.


2.4. Customer incorrectly installed their Medivators CER-2 Optima AER, resulting in HLD being pulled through the machine, May 2018

A report in the FDA’s MAUDE database states the customer installed their CER-2 Optima AER incorrectly, which resulted in HLD being pulled through the machine during the air purge of the endoscope reprocessing cycle. The residual left behind could potentially cause patient chemical colitis. The AER does not require a Medivators personnel to install the machine. The AER was receiving leak errors with a complaint filed by the facility. A Medivators service engineer was called onsite to investigate the complaint and discovered the AER was incorrectly installed by the facility. The machine was returned to Medivators and was confirmed the air tube was hooked up to the HLD tank, thus not following the IFU for install. The AER was used for about two weeks during the time in which their machine was installed incorrectly with potential for patient chemical colitis. It was reported that employees felt ill from the HLD being leaked into the machine with no specific symptoms being reported. A new machine was ordered with a Medivators field service engineer present to install and ensure following the IFU.
2.5. There was a burning odor emitting from the AER light socket and a small flame coming from the light socket, May 2018

A report in the FDA’s MAUDE database states the user facility stated that a burning odor was emitting from the unit and observed a small flame coming from the light socket. The Steris technician was on site and inspected the washer and identified that the light socket was damaged. The Steris technician reported the issue is attributed to improper insertion of the light bulb into the light socket causing an electrical arc to occur. The light socket was replaced by the technician and ran a test cycle, confirmed the unit was operating properly. The technician counseled the facility personnel on the proper way to insert the light bulb, ensuring it is fully seated in the socket. The unit was installed in 2010 and is under Steris service agreement for maintenance activities.

2.6. Blue residue remaining in Endoscopes and hookup tubing after reprocessing in the Advantage Plus Automated Endoscope Reprocessors, April 2018

A report in the FDA’s MAUDE database states the facility reported blue residue remaining in Endoscopes and hookup tubing after reprocessing in their Advantage Plus Automated Endoscope Preprocessors. The detergent used during the manual cleaning phase of reprocessing is not getting rinsed out of their endoscopes. There is potential for chemical exposure to patients which could cause chemical colitis. The clinical education specialist reported the blue residue has only been observed when using certain hookups. The CES also reported the staff were not properly flushing the endoscopes after using intercept detergent. The Medivators specialist confirmed proper operation of their Advantage Plus AERs.

2.7. During a yearly in-service with Medivators clinical education specialist reported the facility was using the incorrect hookups for endoscopes, March 2018
A report in the FDA’s **MAUDE** database states the clinical educator from Medivators was performing a yearly in-service at the facility and reported they were using the incorrect hookups with their endoscopes while reprocessing in the DSD-201 AER. There is potential that the endoscopes were not properly high level disinfected, and potential for patient cross contamination. The CES educated the users on correct hookup use and placement as well as provided information documentation. There have been no reports of patient harm.


### 2.8. Facilities experiencing a white residue being left on Olympus endoscopes after reprocessing in AERs, March 2018

A report in the FDA’s **MAUDE** database states Medivators received information from facilities which are experiencing a white residue being left on Olympus endoscopes after reprocessing in Advantage Plus AERs and other AERs. The facility temporarily suspended all elective GI procedures to investigate cause and identify the residue. The residue was identified as a silicone-based compound when numerous tests were performed by third party labs. Medivators performed an internal investigation after requesting a copy of the test reports performed by each lab. The results identified the residue as poly butyl methacrylate which is a chemical commonly used as the adhesive compound on the back of tape, labels and stickers. It was noted that when the AERs were removed from the HLD process and replaced by manual HLD, the residual was still found. All endoscopes are being inspected after reprocessing and removing any remaining residual using isopropyl alcohol prior to using for procedures. To date there have been no reports of patient harm.


### 2.9. SD-201 Automated Endoscope Reprocessor was programmed with the incorrect number of rinses required for HLD, December 2017

A report in the FDA’s **MAUDE** database states that their DSD-201 AER was programmed with the incorrect number and contact time of rinses for the HLD that was being used. Metricide HDL requires 3 minutes at 1 minute each, with the facility that was reprocessing the endoscopes had the program set at 2 rinses at 30 seconds each. Over the phone, Medivators instructed the facility how to set the machine back to the correct program. The DSD-201 user manual states that the user is instructed to verify the program settings are appropriate for the disinfectant being used prior to reprocessing.
scopes. There is potential chemical colitis or irritation to patients that come into contact with improperly rinsed scopes and there have been no reports of harm to patients.


3. Water Quality Issues

3.1. Olympus was Informed Several Bronchoscopes Model #s BF-260, BF-1T260, and BF-F260 Tested Positive for Fungus as a result of Microbiological Culturing Testing by the Facility, March 2018

The report in the FDA’s MAUDE database states that the sample collected from three BF-260 and one BF-1T260 tested positive for fungus. The Olympus Bronchoscopes were used on seven out eight patients who tested positive for fungus. It was reported that six patients were doing well, but one patient was still ill. There is no information about the other patients’ outcome. The Bronchoscopes were used to obtain bal samples, however Olympus is unsure as to whether the ball samples were positive or negative. Reports 1-4 of 4.


The sample collected was from one BF-F260, two BF-260 and one BF-1T260 tested positive for fungus. The customer had been investigating causes of a possible outbreak of environmental contamination in a number of Bronchoalveolar lavage (bal) samples taken using flexible bronchoscopes and non-Bronchoscopes and non-Olympus Bronchoscopes in the last four months. Model BF-260 was used on patient one, two and seven. Model BF-F260 was used on patients three, four, five and eight. Patient six a non-Olympus rigid scope was used. It was confirmed there was no irregularity of the subject device when Olympus reviewed the manufacturer history. However, Olympus communicated with the user facility and obtained additional information that the Bronchoscopes are dried for a min. of 2 hours and vacuumed packed per normal reprocessing process. A shelf life of 21 days, one Bronchoscope was used in an endoscopy procedure 14 days after expiry date. The hospital is undertaking extra testing to identify where the source of the bacteria Basidiomycetes came from. There is mold in the endoscopy unit and walls were damp where
the mold was. The user conducted weekly water samples from the washer. There was a water failure in December, January, and beginning of February where the washer was taken out of use with no water failures have occurred. The user facility conducted environmental test after cleaning. The test results came back as: high levels of mold grew from pre-assessment rooms and corridor outside, lower levels readings of mold grew form the procedure rooms where the bronchoscopy procedure was conducted, the recovery room, clean scope room and the reprocessing room. A microbiological testing was conducted by a third-party laboratory with results as follows: BF-1T260 tested positive for Staphylococcus and Bacillus (total 7 cfu), BF-260 tested positive for Staphylococcus (11 cfu), BF-F260 tested positive for Gram Negative Bacteria (2 cfu), BF-260 tested positive for Staphylococcus (5 cfu). An exact cause could not be determined at present. Reports 5-7 of 7.


4. Use Errors

4.1. A Bronchoscope was reported to have seven positive cultures following seven Bronchoscopy procedures on seven patients, August 2018

A report in the FDA’s MAUDE database states that the first patient of seven was a morbidly ill male with pre-existing pneumonia and the Bronchoscopy took place in 2018. The user facility reported that the patient expired due to the pre-existing condition. The culture following the first patient had Stenotrophomonas, Achromobacter and an unknown species yeast. An Olympus ESS was dispatched to the user facility to observe the facility and training of user facility personnel. The ESS found the facility to occasionally use a standard bronchoscope in the same procedure before using the Olympus EBUS scope. When the scope is removed it is not immediately precleaned, it is placed asidet in a case potentially used again in the procedure. The ESS advised the facility to discontinue this practice and use a new scope after the EBUS scope. The facility clarified the positive culture for the patient involved was s. Maltophilia and yeast only. After the procedure for precleaning, the scope was wiped on the outside. Bedside cleaner was used to clean the scope and sent through the channel and hand washed on the outside. For manual cleaning, a single use endoscopy brush model 00711-609 was used and placed in an Olympus OER-Pro reprocessing system. The OER-Pro was checked before use and has no reported reprocessing issues. The scope was stored in a hanging cabinet and air drying. The user facility has not had any reprocessing in-service since the OER-Pro was purchased and since have new
reprocessing personnel. An Olympus ESS will be dispatched to the user facility to observe the reprocessing practices and provide training as necessary.


4.2. A Gastrointestinal Videoscope tested positive for unspecified drug-resistant bacteria after being reprocessed twice, August 2018

A report in the FDA’s MAUDE database states OMSC was informed during a surveillance culturing test by the facility that the Evis Exera III Gastrointestinal Videoscope GIF-H190 test positive for unspecified drug-resistant bacteria (number and type of bacteria were not informed) after being reprocessed twice. The scope was cleaned with peracetic acid (neodic septo pac). No other details were given by the facility and there was no report of patient infection associated with this report. OMSC reviewed the manufacturer history report of the scope and confirmed no irregularity and the exact cause could not be determined at present.


4.3. User Facility is unsure whether a patient had an existing infection with Klebsiella pneumoniae Carbapenemase or Duodenovideoscope was the cause of the infection, July 2018

A report in the FDA’s MAUDE database states that OMSC was informed about a potential patient infection with Klebsiella pneumoniae Carbapenemase which the patient also underwent an ERCP procedure using the Evis Exera II Duodenoscope TJF-Q180V. It is unclear whether the reported infection was the cause of the scope or already existing before the procedure. The user facility has started its own investigation and is presently unclear where the infection comes from. There was no reprocessing deviation confirmed by the facility. OMSC was informed that during a periodically microbiological testing by the facility, microbes were found on the scope: Klebsiella pneumoniae Carbapenemase, pseudomonas Aeruginosa and Citrobacter freundii with the number of microbes unknown. The user reprocessed the scope with a non-Olympus AER using non-Olympus chemicals. This scope has been returned to Olympus and sent the scope to a third-party laboratory for microbiological testing. The results from testing the sample collected from the air/water channel of the subject device tested positive for the unspecified microbes (1 cfu/ml). After reprocessing the scope was sent to a third-party again for additional testing and no microbe was detected. No
irregularity was confirmed for the history of the scope when reviewed by OMSC. Exact cause could not be conclusively determined at this time.


4.4. One of three scopes cultured positive after reprocessing three different times, July 2018

A report in the FDA’s MAUDE database states three Evis Exera II Gastrointestinal Videoscopes (2 GIF-H180J scopes) and (1 GIF-XTQ160 scope) were cultured positive (bacteria unknown) after reprocessing three different times. The cause of the event could not be determined, and evaluation is still in progress. The scopes were sent to an off-site independent lab for microbial testing and ethylene oxide sterilization. An ESS was dispatched to the user facility to observe the reprocessing practice and provide training and is still in progress.


4.5. An employee experienced a burning sensation while unloading instruments that were processed in a V-Pro Max sterilizer, June 2018

A report in the FDA’s MAUDE database states that at a user facility an employee experienced a burning sensation while unloading instruments that were processed in a V-Pro Max sterilizer. The employee was not wearing proper PPE and there was no medical treatment sought or administered. There are two V-Pro Max sterilizers at the user facility and could not confirm which unit the reported event occurred on and reviewed the units cycle printouts confirms that the cycles completed successfully for both units. A Steris service technician inspected the sterilizers and found both units to be operating properly with no issues of the functions or operations were identified and were returned to service. The technician counseled the personnel on the importance of thoroughly drying instruments and wearing proper PPE while operating their V-Pro Max sterilizer. No additional issues were reported.

4.6. A Gastrointestinal Videoscope test positive during a surveillance culturing test at the facility, June 2018

A report in the FDA’s MAUDE database states OMSC was informed the Evis Exera II Gastrointestinal Videoscope GIF-2TH180 tested positive for bacteria during a surveillance culturing test at the facility. Biopsy channel 1: Staphylococcus aureus (990 cfu/ml), biopsy channel 2: Staphylococcus aureus (1 cfu/ml), auxiliary channel: Staphylococcus aureus (990 cfu/ml). Also, during additional testing the scope tested positive for the following bacteria (18cfu/endoscope). Biopsy channel 1: Coagulase negative staphylococcus (1 cfu/ml), air/water channel: Staphylococcus aureus (990 cfu/ml), auxiliary channel: Micrococcus (1cfu/ml). The reprocessing method at the user facility was not provided from the facility and no report of patient infection associated with the event. OMSC reviewed the manufacture history of the scope and confirmed no irregularity and exact cause could not be determined at present.


4.7. A Duodenoscope tested positive for Escherichia coli, Coagulase negative staphylococcus and Bacillus, June 2018

A report in the FDA’s MAUDE database states that an Evis Exera II Duodenoscope TJF-Q180V culture tested positive for Escherichia coli, Coagulase negative staphylococcus, and Bacillus which Olympus had been informed by the user facility. A mh-507 Olympus brush was used for sampling behind the elevator and the sterile water flush was collected from the tip of the scope. The Duodenoscope was high level disinfected and pre-cleaned twice after each patient use with no patient infection. The scope was returned to Olympus with the evaluation still in progress and will be sent to an independent lab for microbial testing and ethylene oxide sterilization. An Olympus Endoscopy Support Specialist visited the facility to observe the reprocessing practice and provide a reprocessing training. The ESS found no deviation during the visit.


4.8. A Pentax Duodenoscope cultured positive after sampling was performed and yielded a total of 187 CFU, June 2018

A report in the FDA’s MAUDE database states a Pentax model ED-3490TK cultured positive after sampling was performed yielded a total of 187 cfu comprised of the following four isolates: positive
rods- Planococcus species, positive cocci- Staphylococcus epidermidis, positive cocci- Micrococcus luteus, positive cocci- Micrococcus luteus. The scope was returned to Pentax Medical for evaluation. The scope was reprocessed and resampled in accordance to Pentax medical procedures. The resampling yielded 135 cfu with the following three isolates: positive cocci-Kocuria koreensis, positive cocci-Kocuria koreensis, positive cocci-Staphylococcus saprophyticus. On July 2, 2018 the scope was inspected by Pentax Medical service with findings including: channel improperly installed with gap distal body opening, distal cap, fixed typed passed epoxy seal integrity inspection, passed dry/wet leak tests, primary mild scratch inside. The Duodenoscope is currently undergoing repairs.


4.9. A foreign body of “biological appearance” was expelled through the distal end of the instrument channel of the Colonovideoscope, June 2018

A report in the FDA’s MAUDE database states that during a colonoscopy procedure for Polypectomy, a foreign body of “biological appearance” was expelled through the distal end of the Evis Exera LLL Colonovideoscope when a snare was pushed through the channel. There was no patient infection and the procedure was completed successfully. The scope was reprocessed by manual cleaning and a non-Olympus endoscope reprocessor (Soluscope) two days prior to the incident and not use until day of procedure. The scope was returned to Olympus for evaluation to which the manufacturer history was reviewed of the scope and confirmed no irregularity and the exact cause could not be determined because evaluation is still in progress.


4.10. During a routine culturing test conducted on March 12, 2018, the Colonovideoscope tested positive for bacteria, May 2018

A report in the FDA’s MAUDE database states that during a surveillance culturing test conducted on March 12, 2018 by the facility, the Colonovideoscope tested positive for the following bacteria. Suction channel: Micrococcus spp. (2 cfu/50 ml), environmental bacteria (1 cfu/50 ml). Air/water channel: Micrococcus spp. (2 cfu/50 ml), Staphylococcus epidermidis (1 cfu/50 ml). Auxiliary channel: environmental bacteria (1 cfu/50 ml). There was no microbial growth for the instrument channel. With additional surveillance culturing test by the user facility the, Colonoscope tested positive in the Auxiliary channel: Staphylococcus xylosus (3 cfu/30 ml), instrument channel: Staphylococcus spp. (28
cfu/30 ml), Staphylococcus xylosus (7 cfu/30 ml), suction channel: Staphylococcus spp. (1 cfu/30 ml), Kocuria Kristinae (3 cfu/30 ml). No microbial growth in the air/water channel with additional testing. A non-Olympus AER (Soluscope 3, Soluscope 4) with peracetic acid was used to reprocess the Colonovideoscope. The scope was returned to Olympus and sent to a third-party lab for additional microbiological testing, which the scope tested positive for Bacillus spp. (2 cfu/100 ml) but test result cleared French guideline. No irregularity with manufacturing history of the scope. The exact cause could not be determined at present.


4.11. A Colonovideoscope tested positive after multiple microbiological testing by the user facility, May 2018

A report in the FDA’s MAUDE database states that a user facility performed multiple microbiological testing by the user facility with microbes found from the sample collected from the Colonovideoscope CF-H180AI. The scope was reprocessed using peracetic acid with no report of patient infection. First test unspecified microbes (59,375 cfu/100 ml), second time (556 cfu/100 ml), third time (1,176 cfu/100 ml), geotrichum number of microbes is unknown. Fourth time, suction channel unspecified microbes (5,000 cfu/100 ml), auxiliary water channel: no microbe air/water channel: no microbe: no microbe, fifth time, unspecified microbes. The scope was returned to Olympus and sent to a third-party lab for additional microbiological testing. The testing indicated no microbial growth for all channels. No irregularity with the manufacturing history of the scope. The exact cause could not be determined at this time.


4.12. During a Polypectomy, fine dark grey graphite powder leaked out from the Colonovideoscope, May 2018

A report in the FDA’s MAUDE database states that a Colonovideoscope had find dark grey graphite powder leaked out and fell off within the bowel of the patient. The patient did not incur injury associated with this event. It was reported that the powder fell off from the subject device and air leakage was noted during the cleaning process after the procedure. OMSC did not receive the scope however, the manufacturing history of the scope was reviewed and confirmed no irregularity. The exact cause could not be determined at this time.
4.13. Olympus sent device testing positive for Micrococcaceae to a third-party laboratory after repeated test were performed, May 2018

A report in the FDA’s MAUDE database states the European Version Cystonephrofiberscope CYF-5 was sent to a third-party laboratory for microbiological testing. The scope was sent to Olympus and not OMSC. The testing results from the sample collected from all channels of the scope tested positive for Micrococcaceae (1 cfu). The results did not clear the French guideline. The repair history shows the insertion section of the scope has been replaced in September 2017. The exact cause could not be conclusively determined at this time.

4.14. A Cystonephrofiberscope tested positive for Staphylococcus aureus after microbiological testing, May 2018

A report in the FDA’s MAUDE database states the OMSC was informed of the results of microbiological testing by the user facility, the Cystonephrofiberscope CYF-5 tested positive for Staphylococcus aureus. The scope was returned to Olympus and was sent to a third-party lab for testing, no microbe was detected from the sample collected from all channels of the scope. The user facility manually processed the scope with peracetic acid and no report of infection. OMSC reviewed the scope history and confirmed no irregularity. Exact cause of reported event could not be determined at this time.

4.15. Gastrointestinal Videoscope tested positive during a surveillance culturing test by the facility, April 2018

A report in the FDA’s MAUDE database states that OMSC was informed that during a surveillance culturing test by the facility of an Evis Exera III Gastrointestinal Videoscope GIF-H190, the suction and auxiliary channel tested positive for bacteria. Suction channel: pseudomonas aeruginosa (>100 cfu/100ml), Enterobacter (>100 cfu/100 ml). Auxiliary channel: unspecified bacteria (3 cfu/100 ml). The result indicated not microbial growth for the air channel. The scope had been reprocessed using a
non-Olympus AER (Wassenburg wd440) with peracetic acid. No patient infection reported with the event. The scope was returned to Olympus and sent to a third-party lab for additional microbiological testing and the results indicated no microbial growth for the scope and cleared guideline. The manufacture history was reviewed and confirmed no irregularity. Exact cause could not be determined at present.


4.16. **Multiple testing by the user facility, microbes were detected from sample collected**, April 2018

A report in the FDA’s MAUDE database states Olympus was informed as a result of multiple testing by the user facility, microbes were detected from the sample collected from the Cystonephrofiberscope CY-5. The first time tested 1 cfu/100 ml, second testing 3 cfu/100 ml, third testing 8 cfu/100ml all unspecified microbes. Pseudomonas 1 cfu/100 ml, and Stenotrophomonas 1 cfu/100 ml were found. The scope had been manually reprocessed using peracetic acid with no reports of infection associated with this report. The scope was not returned to OMSC for evaluation.


4.17. **Patient experiencing fever and chills post procedure went to the ER after a Ureteroscopy and stent placement**, April 2018

A report in the FDA’s MAUDE database states a patient went to the ER experiencing fever and chills, was found to have an infection and was treated with augmentin-antibiotics. The performed procedure was a Ureteroscopy with left laser lithotripsy and stent placement. The Ureteroscope used was a Uretero-Renoscope Semi-Rigid Ureteroscope 27010KA and was returned for microbial testing, customer believes the scope may have been involved with a patient infection. The customer indicated the scope did not malfunction and no physical issue with it. The scope was received at Karl Storz Logistic Center where the channels were sampled with a brush-flush-brush technique with sterile water and a new cleaning brush to recover potential contamination inside the scope. Sterile water from the channels was collected in a sterile sample cup and negative control sample was prepared using same lot of sterile water, cleaning brush and sample cup. Sample from device and negative control sample labeled and shipped to Nelson Labs for microbial analysis. There were no colony forming units detected within the channels of the endoscope.
4.18. The user facility conducted a microbiological test on the suction channel of a Colonovideoscope, April 2018

A report in the FDA’S MAUDE database states the user facility conducted microbiological testing and the Colonovideoscope CF-H190I tested positive for bacteria of Staphylococcus aureus, Enterobacteria, Pseudomonas sp, Stenotrophomonas maltophilia, Acinetobacter sp and Candida (>200cfu/endoscope). The scope was disinfected using non-Olympus AER Soloscope series 4 with peracetic acid. The Scope was sent to a third-party laboratory for additional microbiological testing and tested positive for bacteria gram positive (3cfu/100ml) but testing result cleared guideline.

4.19. Guidewire and a laser probe could not pass through the instrument channel of the Ureteroscope, February 2018

A report in the FDA’s MAUDE database states that Olympus was informed of the incident that during a tul (Transurethral Ureterolithotomy) procedure, a guidewire and a laser probe could not pass through the instrument channel of the Uretero-Reno Videoscope. The Uretero-Rneo Videoscope URF-V has been returned to Olympus Medical Systems Corp. for evaluation due to a hole on the instrument channel at 47cm from the distal tip, and an air leak was found at the point. Shavings were piled up inside the instrument channel which clogged the channel. The conclusion was made that the instrument channel might be shaved due to inserting endo therapy accessory forcibly which causes the shavings to clog the instrument channel that caused the reported event. There was no injury to the patient with this event.

4.20. Baystate Medical Center warns patients after unclean Colonoscope discovered, Massachusetts, January 2018

SPRINGFIELD- Baystate Medical Center has warned 49 patients who received bowel surgery that the colonoscope used in their surgeries may not have been cleaned properly. One single channel on a
colonoscope had not been cleaned properly. This was a similar incident that had happened at Baystate Nobel Hospital in Westfield that occurred in 2015. The colonoscope in question has been in limited use over the past few years. Patients were notified by Baystate staff members over the phone and by letters and were given a number to call to which the hospital did not make public.

In 2015, 293 patients who had colonoscopies at Noble Hospital during from June 2012-April 2013, were notified by Baystate Health stating that “their procedures had put them at risk to exposure to blood-borne pathogens such as hepatitis B, hepatitis C, and HIV”. The technicians at Noble failed to sterilize the one channel on the colonoscope.

The Republic documents obtained from the Department of Public Health, in a public record request showed that an employee tried to get Noble management to address the issue before going to the Massachusetts Department of Health.

Jim Kinney, jkinney@repub.com (Jan 30, 2018), The Republic, Baystate Medical Center warns patients after unclean colonoscope discovered, from https://www.masslive.com/news/index.ssf/2018/01/baystate_medical_centerwarns.html

4.21. Twenty-Three patients Test Positive for Mycobacterium chelonae from Bronchoalveolar lavage samples, January 2018

A report in the FDA’s MAUDE database states the 23 patients tested positive for Mycobacterium chelonae from bronchoalveolar lavage (BAL) samples. A total of 19 bronchoscopes were reportedly used to examine the patients. The user facility did not provide specific information regarding the mode/serial number of the bronchoscopes used on patients. It is unknown if the positive bal samples are due to pre-existing conditions of the patients or due to unspecified laboratory issues. The Olympus BF-XT160 Bronchovideoscope has not been returned to Olympus for evaluation. An Olympus endoscopy support specialist was sent to the user facility on 2017, where several reprocessing deviations was noted during the visit: facility was not precleaning, leak testing was not done properly, the leaker tester was removed from the scope while submerged in the water.

https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfMAUDE/detail.cfm?mdrfoi__id=7180785&pc=EQQ

4.22. Nine patients tested positive for mold spores after undergoing unspecified Bronchoscope procedures, January 2018
A report in the FDA’s MAUDE database states that limited information was obtained when Olympus made multiple follow up telephone calls to the user facility and in writing to gather additional information on the reported events. An Olympus endoscopy support specialist (ESS) was sent to the facility to observe the reprocessing practice and provide additional training. The scope was returned to Olympus on February 2, 2018 for unspecified damage which had critical dents on the insertion tube. The scope was serviced and returned to the facility.

https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfMAUDE/detail.cfm?mdrfoi__id=7267525&pc=E0Q

4.23. Samples show that Mycobacterium Tuberculosis grew from two patients after a bronchoscopy procedure, January 2018

A report in the FDA’s MAUDE database states that Olympus was informed of two patients were examined by the same bronchoscope on two different dates. The facility reported that the bronchoalveolar samples collected from both patients tested positive for Mycobacterium. An Olympus field service engineer visited the facility to evaluate the device and provide preventative maintenance, and reprocessing training on the AER (Automated Endoscope Reprocessor). In January 2017, the field service engineer looked at the error log files of the oer-pro and assisted the staff in obtaining water samples to be tested at an independent lab for microbial testing. It was discovered that the last water line disinfection was performed on October 8, 2015. The field engineer found the drain hose pushed down into the water drain trap, coming into contact with water found inside the trap. An in-service was conducted to demonstrate the proper use of the AER to the staff at the user facility on January 23, 2018.

https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfMAUDE/detail.cfm?mdrfoi__id=7272402&pc=E0B

4.24. Three patients infected with the association of two contaminated Bronchoscopes, January 2018

A report in the FDA’s MAUDE database states that Olympus was made aware of that two Bronchoscopes BF-H190 may have been contaminated and likely caused three separate patients to become infected with Mycobacterium abscessus. The Bronchoscopes were returned to Olympus for evaluation with the results pending and the investigation is ongoing. The user facility reported that in 2017 that two Bronchoscopes were sent to the lab for culturing due to possible cross-contamination and tested positive for Mycobacterium abscessus. It was reported by Olympus personnel that the facilities reprocessing practices were not being followed: with incorrect leaking testing and the
duration was too short, the angulation levers were not turned during the leak test as well as the duration of suction of detergent/water through the channels was too short, and not wiping of the insertion tube. The endoscopes were placed in the AER incorrectly with the insertion tube pressed up against the lid of the AER during the reprocessing cycle. The patients received treatment and their condition is unknown.

https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfMAUDE/detail.cfm?mdrfoi__id=7202843&pc=EQQ

4.25. The distal end of the Uretero-Reno Videoscope broke inside the patient and caused injury to the patient, January 2018

A report in the FDA’s MAUDE database states that the distal end of the Uretero-Reno Videoscope URF V-2 broke inside the patient and there was injury to the patient during an unspecified procedure. Additional medical intervention was required to remove the subject device from the patient and the procedure time was extended. Olympus was notified of the incident and has not been returned to Olympus Medical Systems Corp.


4.26. Guidewire coating chipped away during procedure while using a Ureteroscope, January 2018

A report in the FDA’s MAUDE database states that after the doctor asked for a second guidewire, he ran the semi-rigid Ureteroscope WA02946A over the wire. He tried to remove the wire through the scope with little difficulty, but once it was removed he notice some of the coating was chipped away. There was a lot of edema and the doctor used the scope to verify that none of the coating had chipped off, so a stent was placed inside the patient.


4.27. Three times cultures were found on a Colonoscope that was conducted by the user facility, January 2018

A report in the FDA’s MAUDE database states surveillance culturing was conducted on an EVIS EXER LLL Colonovideoscope CF-H1901 by the user facility and microbes were detected three times. First time
microbes were found >100 CFU Aeromonas hydrophila, Aeromonas caviae, Klebsiella oxytoca. Microbes were found a second time in the Colonoscope with >100 CFU Bacillus and Burkholderia cepacian complex. The third surveillance culturing found >100 CFU Bacillus, Burkholderia cepacian complex and Citrobacter freundii. The scope was reprocessed in an AER Serie 3 with peracetic acid according to the instruction manual. The exact cause of the event could not be conclusively determined.


4.28. Endoscope Reprocessing Technician experienced chemical exposure symptoms after handling an endoscope, January 2018

An Endoscope Reprocessing Technician suffered from chemical burns and skin discoloration after handling an endoscope and other items that were reprocessed in their Advantage Plus AER. It was determined that the technician improperly reprocessed the scope which caused the chemical exposure. The facility’s biomedical service technician and Medivators field service engineer evaluated the AERs and conducted test cycles, concluding that the unites operated within specification. During the FSE’s visit, a plastic container of reusable valves, buttons and other items were placed in the AER along with the scope for reprocessing in place of using a mesh bag that the Medivators provide with the AER. The plastic container is not validated for the use with the Advantage Plus AER which could potentially cause the accessories to not be properly high level disinfected.

Medivators regulatory affairs followed up with the facility’s biomed and stated the chemical exposure was due to a handling issue during the reprocessing process and have changed their process accordingly. The technician received medical attention at their hospital and is recovering well.


4.29. Blue residual fluid dripping from Olympus Endoscopes while hanging in a storage closet, January 2018

A report in the FDA’s MAUDE database states that a facility reported blue residual fluid dripping from their Olympus endoscopes while hanging in their storage closet after it was reprocessed in their Advantage Plus AER. The facility did continue to use the endoscopes on patient with the fluid dripping from the scopes. A Medivators field service engineer confirmed the AER was properly functional and instructed the facility to collect a sample of the blue fluid if it occurs again. The FSE also noted that
manually leak testing was not being performed prior to disinfection as instructed per the IFU. Leak testing is performed to detect any leaks or tears in the endoscope which can allow fluid to accumulate and cause cross contamination. No harm to patients has been reported.


4.30. Facility reported a waxy green substance in the basin of their Advantage Plus AER, January 2018

A report in the FDA’s MAUDE database states a facility reported a waxy green substance in the basin of their Advantage Plus AER and on the endoscopes, which can cause potential harm to patients. The Medivators field service engineer evaluated the facility and took samples of the waxy green substance to be analyzed. The FSE noticed that maintenance was not being performed on the unit specifically the basin drains when they cleaned the build up from the basin. He informed the facility that maintenance is done on a monthly basis that is stated in the user manual. It is still unknown what is causing the waxy green substance in the AER and Medivators are working continuously with the facility to investigate what it is and where it is coming from. There has been no harm done to patients.


4.31. Five patients that acquired infections from a contaminated Fiber Bronchoscope, December 2017

A report in the FDA’s MAUDE database states that Pentax medical was made aware of a report for the medicines and health products safety of cross contamination of a fiberscope FB-18RBS to five patients. Two cases of pneumonia acquired lung disease under ventilator (vap) to pseudomonas aeruginosa and stenotrophomonas maltophilia. The bronchial fiberscope was removed in 2017 and an antibiogram indicates a pseudomonas aeruginosa and stenotrophomonas maltophilia was present. Three of the five patient are deceased but did not attribute to vap, one patient was discharged, and one patient is in the intensive care unit. In 2018, Pentax received the device for service requested by the customer, which revealed a perforated bending rubber and a crushed/buckled insertion flexible tube. The hospital staff did not comply with Pentax instructions for use when reprocessing the bronchoscopes.

5. Gram Negative Bacteria Outbreaks

5.1. Patient tested positive for Enterococcus casseliflavus infection after undergoing an ERCP procedure, July 2018

A report in the FDA’s MAUDE database states that patient upon admission presented with a positive blood stream enterococcus casseliflavus infection prior to undergoing an ERCP with an Evis Exera II Doudenovideoscope TJH-Q180V. A second patient had the same scope used on them two days later and has tested positive for the same bacterium. The patient’s course of treatment and condition is unknown. The nurse reported the source infection is unknown and the scope cannot be ruled out. Pre-cleaning was performed and transported to the endoscopic room in an approved transport bin. An ESS visited the user facility to observe the reprocessing practice on August 15, 2018. It was noted a minor deviation as the staff used a 60 cc or 20 cc (2x) syringe for flushing the elevator area after brushing. The staff was advised the TJF-Q180V manual recommends a 30 cc syringe to be used, and at all other reprocessing steps were performed in accordance with the manufacturers recommendations. The scope was returned to Olympus for evaluation and still in progress. The scope will be sent to an independent lab for microbial testing and ethylene oxide sterilization.


5.2. Carbapenem-resistant Enterobacteriaceae outbreak with multiple patients infected and reported to Olympus, May 2018

A report in the FDA’s MAUDE database states physicians are unsure if the Bronchovideoscope BF-P190 caused or contributed to the patient infection outbreak. Olympus made multiple follow ups with the user facility by telephone and in writing in an attempt to gather additional information on the reported event. The scope was returned to Olympus for evaluation, the device evaluation is still pending completion. The scope will be sent to an independent laboratory for microbial testing and ethylene oxide (ETO) sterilization. An Olympus endoscopy support specialist visited the user facility to observe the facility’s reprocessing practice and provide reprocessing training. The specialist observed one minor deviation, the staff used a 30cc syringe to aspirate 90cc of fluid into the scope. The specialist provided the user facility staff a reprocessing wall chart and a DVD step by step video on how to reprocess a bronchoscope.

https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfMAUDE/detail.cfm?mdrfoi__id=7559224&pc=EQQ
5.3. Samples Were Taken from Ten Patients that were growing Pseudomonas Aeruginosa, Serratia Marcescens, April 2018

A report in the FDA’s MAUDE database states that C&S obtained during a bronchoscope procedure model 1T180 of ten patients were all growing pseudomonas Aeruginosa, Serratia marcescens. This was traced back to index patient with these organisms including Chryseobacterium indologenes in the sputum. Three of the patients cultured included Chryseobacterium indologenes, and three grew Enterobacter and one grew strep pneumonia. With further investigation, the bronchoscope was used on all the aforementioned patients. The cultures of the bronchoscope revealed 2+ Serratia marcescens, 2+ Chryseobacterium indologenes, 2+Enterobacter cloacae, and 2+pseudomonas aeruginosa. The Bronchoscope 1T180 also had a loose cap on biopsy port and was cultured to reveal 2+ growth of Serratia marcescens, 2+ growth of Chryseobacterium indologenes, 2+ growth of Enterobacter cloacae, and 2+ growth of pseudomonas aeruginosa. No patients developed an infection related to this issue and no issues were identified related to high level disinfection.


5.4. Foreign material was found present in a Colonoscope during a diagnostic Colonoscopy, December 2107

A report in the FDA’s MAUDE database states the user facility reported that during a diagnostic Colonoscopy, the user experienced difficulty passing a biopsy forceps through the channel of the colonoscope. It was reported that a hard, white, crusty substance came out with the retracted biopsy forceps. Patient was exposed to foreign material, but it is unknown if the substance had fallen inside the patient. A different scope was used, and the procedure was completed, the patient was held at the operating room for monitoring. The Colonoscope PCF-H180AL was returned to Olympus for evaluation and found that the scope failed a leak test due to a damaged biopsy channel (cut/hole), which is due to user mishandling. A small white foreign material was noted inside the biopsy channel port size approximately 1x1.5mm but the material is not hard or crusty looking. Both the foreign material and the biopsy channel will be forwarded to an off-site lab for analysis.


5.5. Four Patients Tested Positive for Drug-resistant Klebsiella pneumonia After Having Undergone ERCP, October 2017

A report in the FDA’s MAUDE database states that four patients tested positive for OXA-48 producing Klebsiella pneumonia after having undergone endoscopic retrograde cholangiography (ERCP) with an
Olympus TJF-Q180V duodenoscope in a foreign healthcare facility. OXA-48 is an enzyme that breaks down carbapenem, one of the antibiotics used to treat multidrug-resistant bacterial infections. The duodenoscope had its forceps elevator replaced in 2016.


5.6. An Olympus Colonovideoscope Linked to *Salmonella zanzibar* Infection, October 2017

A report in the FDA’s MAUDE database states that *Salmonella zanzibar* was found in fecal samples of all five patients who underwent colonoscopies with a particular Olympus colonovideoscope, model CF-HQ190I. Evaluation of the device showed no irregularities and the exact issue could not be determined.


5.7. An Endoscope With a ‘Design Issue’ Has Been Linked to Probable Transmission of a Colistin-Resistant Superbug, U.S., April 2017

A regulatory report filed by Pentax with the FDA reveals that an ED-3490TK duodenoscope was likely responsible for the transfer of a colistin-resistant strain of CRE from patient to patient. Colistin is an antibiotic known as the “last resort” antibiotic. This is the first known case of a colistin-resistant strain of CRE being linked to patient to patient transfer via duodenoscopy. As many as five patients may have been exposed to the contaminated duodenoscope.


5.8. Carbapenem-Resistant *Klebsiella pneumoniae* Cluster Associated with Gastroscope Exposure among Surgical Intensive Care Unit Patients at University of Pittsburgh Medical Center, Pennsylvania, October 2016

At the University of Pittsburgh medical center, an increase in carbapenem-resistant *Klebsiella pneumoniae* (CR KP) isolates was observed in the surgical intensive care unit. Three new cases were identified in one month compared with the average of 0.5 new cases/month from the previous year. Three additional cases were identified who had exposure to the surgical intensive care unit, but whose CR KP isolates were recovered in another unit. Review of the 6 cases found that all cases were exposed to the same OR gastroscope. Boroscopy revealed several deep scratches and luminal debris in the
gastroscope. It then underwent channel replacement and cultured negative prior to going back into service. No further cases were identified.

http://ofid.oxfordjournals.org/content/3/suppl_1/248.full

5.9. Nurse claims University of Cincinnati Health failed to stop infectious outbreak, Ohio, June 2016

A University of Cincinnati Health nurse filed a lawsuit against the health system, claiming it failed to prevent the spread of multidrug-resistant bacteria and covered up its role in the outbreak.

According to the report, as many as 100 patients may have developed an infection as a result of the care they received at UC Health. The lawsuit claims UC Health launched an investigation after recording a spike in the number of infections in patients who had undergone a bronchoscopy. Allegedly, the nurse suggested reaching out to an outside agency to investigate the medical devices and infections but was told "no" because the organization didn't want an audit.

The news reported that the health system decided to simply deal with the patient infections rather than tackling the root of the problem, which were the bronchoscopes being used for the procedure.

The health system had stopped checking the bronchoscopes. By no longer checking the scopes the system wasn’t going to find any problems so there would be no need for an outside audit.


5.10. CRE death linked to ERCP procedure at Lehigh Valley hospitals, Pennsylvania, April 2016

A patient at the Lehigh Valley hospital in PA underwent an ERCP procedure and soon thereafter was diagnosed with severe sepsis, septic shock and acidosis. She was admitted to the intensive care unit and, weeks after the procedure the doctor delivered the news that she had been infected with antibiotic resistant bacteria from a contaminated endoscope. She died a few weeks later.

The patient was one of as many as 350 patients at 41 medical facilities in the United States and worldwide who were infected or exposed to contaminated scopes from Jan. 1, 2010, to Oct. 31, 2015, according to a U.S. Food and Drug Administration document obtained by the House Committee on Oversight and Government Reform and made public in mid-April.

5.11. Multidrug-Resistant *E. coli* Infects Patients at University of Colorado Hospital, Colorado, January 2016

Nine University of Colorado Hospital patients developed infections after undergoing surgeries with a duodenoscope. Three of the patients have died, although it is unclear what role these infections played in their deaths. The hospital has notified patients, families, and other patients who had undergone surgery with the same suspect endoscope. A visual inspection of the scope at Olympus found "the bending section adhesive was whitish in color and had open gaps at each side of the bending section cover, the glue around the nozzle had signs of cracks and gaps," and "the insertion tube had multiple buckles throughout the entire length." A microscopic inspection also discovered brown stains.


A study conducted involving the genetic marker, *clpK*, which increases the heat resistance of a strain of *Klebsiella pneumonia*, revolved around a recent outbreak in Norway. Five patients and one intubation endoscope were found to have the *clpK* marker at an intensive care unit in a secondary care hospital. The bacteria survived within the endoscope despite going through a chemothermal disinfection process in a decontaminator. The study found, through testing after heat treatment, the survival rate was strongly dependent upon the *clpK* marker. Due to the potential of heat resistance of certain strains of *K. pneumonia*, this allows for possible spreading and infection to other areas of the hospital.


5.13. *Psuedomonas* outbreak at Huntington Hospital in Pasadena, California, August 2015

On August 19th, 2015 Olympus contacted Huntington Hospital after a news report about patients being sickened after scope procedures at the hospital. The hospital informed Olympus that the patients had died. At least 3 patients are reported dead. It is not clear how many were exposed and whether only three have passed. The report in the FDA database shows a different scope than the one recalled in January.


On March 4th, 2015 Hartford Hospital in Connecticut contacted 281 of their patients who could have been exposed to a strain of *Escherichia coli* (*E.coli*). Two scopes that could have infected 281 patients were removed from service in December. The hospital has been active, calling the patients to let them know and ask them to come in for screening. Dr. Rocco Orlando of Hartford Hospital stated that there is a defect in this particular scope that makes it nearly impossible to be completely disinfected and that the process for cleaning their endoscopes was followed. The medical device that was used was the same one that officials at Ronald Reagan UCLA medical center said was used when seven patients were infected by the “superbug”. Hartford hospital has notified the Department of Public Health and that they are monitoring the situation.


5.15. **CRE Outbreak at Cedars-Sinai in Los Angeles**, California, March 2015

On March 4-2015, health officials at Cedars-Sinai hospital in Los Angeles announced that 4 patients were infected with CRE (Carbapenem-Resistant Enterobacteriaceae) and that 67 additional patients might have been exposed as well. Investigators started testing for CRE after a similar outbreak occurred at UCLA Medical Center last month. A single ERCP (Endoscopic Retrograde Cholangiopancreatography) scope was identified as the source of the outbreak and was used from August 2014 – February 2015. Officials at Cedars have since removed the scope from use and have decided to increase the safety measures associated with all scopes. As with other cases across the country, health officials found no cleaning flaws and that the cleaning was performed according to the manufacturer’s directions.


In North Carolina on February 22, 2015, officials made a statement that two people died from CRE and infected a dozen others. So far this year, three people have acquired CRE at Carolinas Healthcare System hospitals and additional 15 have come into hospitals with existing CRE infections. CRE affects sick patients who are in facilities for a long time or who use devices like ventilators, urinary catheters, and endoscopes. Carolinas HealthCare has changed how they clean their devices. Because of the
increase, officials said that the Charlotte-based hospital systems have started screening patients who likely have CRE, once they are identified; these patients are isolated from other patients and once they are released, extra steps are being taken to decontaminate their rooms.


5.17. CRE Outbreak at University of California, Los Angeles (UCLA), California, January 2015

At UCLA’s Ronald Reagan Medical Center, five patients were infected with CRE and two others died from CRE infections. These infections are all associated with contaminated endoscopic retrograde cholangiopancreatography (ERCP) duodenoscopes. 179 other patients also received treatment with these scopes and may have been exposed to CRE. UCLA says that the dirty scopes were washed according to the directions provided by the manufacturer. UCLA has now implemented a new decontamination process for the scopes that “goes above and beyond the manufacturer and national standards.” The CDC is assisting the L.A. County Department of Public Health look into these infections at UCLA. According to the FDA, work is being done to prevent the spread of infections while still allowing these tools to be used.


5.18. A Genetic and Epidemiological Analysis of Antibiotic-Resistant Enterobacteria Identifies an Endoscope as the Possible Source of an Outbreak, France, 2012-2014

A genetic investigation of OXA-204, an enzyme that breaks down carbapenem, lead researchers to trace the origin of an outbreak. Carbapenem is an antibiotic that is prescribed to treat patients with multidrug-resistant bacterial infections. Bacteria with the gene that produces OXA-204 are resistant to carbapenem. Isolates of bacteria with OXA-204 were sent to the National Reference Center for Antibiotic Resistance during 2012-2014. Seventeen patients that had bacteria with the OXA-204 gene isolated from them had direct contact with a specific endoscope. In February 2014, the endoscope was retired from use and colonization of patients by the bacteria in question stopped. No bacteria with OXA-204 were recovered from the device, but gram-negative bacteria were cultured.


5.19. CRE Outbreak at Seattle Hospital, Washington, 2012-2014

The Virginia Mason Medical Center in Seattle, Washington blames the contaminated endoscopic ERCP duodenoscopes for the infection of at least 35 patients. These dirty scopes may also have contributed to the death of 11 people. The outbreak occurred between 2012 and 2014. Officials at Virginia Mason did not believe it was necessary to notify the patients. Investigators say the scopes had been properly sterilized according to the manufacturers’ Instructions for Use. Virginia Mason now quarantines all
reprocessed scopes 48 hours prior to scheduled procedure to ensure that there is no bacterial contamination.


5.20. CRE Outbreak at Lutheran General Hospital in Park Ridge, Illinois, December 2013

243 patients underwent the Endoscopic Retrograde Cholangiopancreatography (ERCP) procedure, which is a specific procedure looking at bile ducts and pancreas were screened for potentially being exposed to the bacteria CRE. 105 of 243 patients who may be infected have come in contact with the hospital for screening. The ERCPs involve a process of high-grade disinfectants and brushes in order to effectively clean them. The hospital has since permanently moved to the use of gas sterilization for better cleaning efficacy.


5.21. Outbreak of Hospital Infection from Biofilm-embedded Pan Drug-resistant *Pseudomonas aeruginosa*, Due to a Contaminated Bronchoscope, Turkey, October 2013

An outbreak of colistin-resistant *Pseudomonas aeruginosa* occurred at a hospital in Ankara, Turkey on October 13, 2013. Fifteen patients were infected after undergoing bronchoscopy. *P. aeruginosa* was isolated from the bronchoscope. The hospital’s disinfection and cleaning protocols were modified, but infections still occurred. Ethylene oxide sterilization was introduced to the disinfection protocol, and infections stopped. Scanning election microscopy was used to confirm the presence of biofilm in the bronchoscopes taken out of use.


5.22. Gram-Negative Pneumonia Death Linked to Contaminated Scope, Washington, February 2013

A lawsuit over the death of a retired Navy chief petty officer was filed in November 2015. The lawsuit claims that Veteran Affairs Puget Sound Health Care System contributed to his death by failing to properly sterilize bronchoscopes. The suit claims that the veteran underwent at least two procedures with bronchoscopes from 2009 to 2012 that had not been disinfected according to the manufacturer’s instructions. A nurse, Barbara Deymonaz, who worked at the Puget Sound VA from 2012 to 2013 said that she complained many times about lapses in procedures that may have potentially put patients at risk. The amended lawsuit mentions that the VA used scope-washing machines manufactured by Custom Ultrasonics.
5.23. CRE Outbreak at University of Pittsburgh Medical Center, Pennsylvania, November 2012

In November 2012, an investigation was started at UPMC Presbyterian after multiple patients tested positive for CRE. None of the patients died as a direct result of the infection. As a result of the investigation, 18 patients had matching cultures to an infected scope used in ERCP procedure. During the investigation, UPMC realized that due to a new design, disinfectant was unable to reach all parts of the scope. They have started using ethylene oxide gas sterilization as a new way to clean all gastrointestinal scopes.


5.24. CRE Outbreak National Institute of Health (NIH), Maryland, June 2011

In June 2011 staff members at the Nation Institutes of Health’s Clinical Center started a 6 month fight with antibiotic-resistant Klebsiella pneumoniae that eventually infected 17 patients. The staff attempted to contain the infection after they noticed the first patient became sick, but a few months later a second, third and fourth patient became ill with the same strain of bacteria. After the second round of infections occurred, the infection prevention staff implemented extreme measures including monitoring every patient, swabbing all surfaces, implementing an extreme hand hygiene policy and even disposing reusable equipment after one use. The staff struggled to treat the infected as well. The bacteria quickly developed resistance to experimental antibiotics as well as antibiotics that were thought to be too harmful to the patients. After six months, the infection-control finally caught up to the infections, and the spread of the bacteria was stopped. Ultimately, the most important aspect to stopping outbreaks in hospitals is surveillance.


5.25. Emergence of Glutaraldehyde-Resistant Pseudomonas aeruginosa, Switzerland, November 2009

In November 2009, at the University Hospital of Basel in Basel, Switzerland, staff conducted a routine sampling of endoscopes. The routine sampling was to monitor the efficiency of the endoscope-cleaning procedure at the hospital. During this procedure Pseudomonas aeruginosa (gram negative) was detected. From 40 tested endoscopes in November 2009, 23 of 73 samples detected P. aeruginosa. In the following samples from November through December 2009, P. aeruginosa was detected in 29 of the 99 samples. It was found in the rinsing water and in the drain of 1 of the automated endoscope reprocessors. 2 distinct P. aeruginosa strains were revealed, one in each reprocessor. The
glutaraldehyde-based disinfectant showed no activity against the 2 pseudo outbreak strains when it was used in the recommended concentration under standard conditions. 63 patients who underwent endoscopic procedures from April through November 2009 tested positive for P. aeruginosa. The epidemiologic investigations failed to find a relation in 20 of 63 patients. After medical chart review by 2 infectious disease specialists, lower respiratory tract and bloodstream infections possibly caused by the pseudo outbreak strain were detected in 6 patients. The surveillance of the endoscopes were increased by sampling the rinsing water from the automated reprocessors twice weekly and sampling endoscopes twice monthly.


Gram negative bacteria: Klebsiella pneumoniae was the culprit producing extended-spectrum beta-lactamase outbreak. The investigators reviewed all medical data associated with patients and collected microbiological data from environmental sources and Duodenoscopes. The investigators identified 16 patients that were colonized with Klebsiella pneumonia that produced extended-spectrum beta-lactamase type CTX-M-15. All 16 of these patients had previously undergone ERCP between December 2008 and August 2009 at Hospital G. Montpied in France. The ultimate source for the infection was identified as one Duodenoscope. Audits show that the cleaning and drying was insufficiently performed. After strictly following the cleaning guidelines, the outbreak ended.


5.27. Early Identification and control of carbapenemase-producing Klebsiella pneumoniae, originating from contaminated endoscopic equipment, June 2008- January 2009

A total of seven patients became infected with Klebsiella pneumoniae at two hospitals between June 2008 and January 2009. All seven patients had previously received ERCP within the past two months. Infection control measures were implemented to help prevent the transmission to other patients. There appears to be a link between all seven patients. They all had ERCP done at the same endoscopy center. It was discovered that there was an inadequate cleaning step at the endoscopy center. Investigators found bioburden in the elevator channel of the implicated scope. After identifying this flaw, 46 patients were invited for testing and an extra three patients were identified to be colonized with carbapenemase-producing organisms. The identification of the problem, the source of the problem and implementing infection control measures led to the prevention of an outbreak.

5.28. Pseudomonas aeruginosa outbreak in The Netherlands, 2008

In 2008, an outbreak of multidrug-resistant Pseudomonas aeruginosa occurred at the University Medical Centre Groningen at the University of Groningen in The Netherlands. Three patients became infected with this bacterium after undergoing ERCP procedures. Using both microbiological and epidemiological techniques, the investigators found the source of the infection: one individual ERCP scope. They found no bacterial contamination in the washer-disinfectors, tubing, or anywhere else in the hospital. The isolates found infecting the patients were linked to the isolates from the scope through molecular characterization. Luckily the routine screening of both patients and scopes prevented this outbreak from becoming a larger problem. The surveillance protocol needs to be tightened up to prevent all cases and prevent cross contamination between patients who underwent ERCP.


5.29. Outbreak of Pseudomonas aeruginosa Infection Associated with Contamination of a Flexible Bronchoscope, Georgia, June – July 2007

There was a small outbreak of Pseudomonas aeruginosa infections in June and July of 2007 at Grady Memorial Hospital in Atlanta, Georgia. Isolates were obtained from respiratory cultures of 12 patients. All of the cultures had the same unique antibiogram pattern. The investigators cultured all bronchoscopes at the hospital and identified one as the source of the infection. As soon as this bronchoscope was identified as the source, it was removed from use. After removal of the bronchoscope, there were no more cases of Pseudomonas aeruginosa. 55% of patients exposed to that specific bronchoscope during those two months developed an infection, as opposed to 2% of patients exposed to other bronchoscopes in the same time period. The bronchoscope was evaluated, and there was visible damage to the bronchoscope that prevented effective high-level disinfection. It was determined that the occasional inspection for damage might be required in order to ensure effective high-level disinfection.


5.30. An outbreak of Pseudomonas aeruginosa infections following thoracic surgeries occurring via the contamination of bronchoscopes and an automatic endoscope reprocessor, Japan, May - June 2003

In May and June 2003 an outbreak of Pseudomonas aeruginosa occurred after thoracic surgeries in Kyushu University Hospital in Fukuoka, Japan. Seven patients were reviewed, and it was revealed that the bronchoscopes were used during endotracheal intubation for one-lung ventilation in most patients. P. aeruginosa was recovered from the sputum of these patients at a very early stage after the operation. Samples from the bronchoscopes and an automated endoscope reprocessor were cultured
and *P. aeruginosa* was recovered from all the samples obtained. The sterilization cycles of the bronchoscopes were inspected, and it revealed unsuitable management of bronchoscopes and a flaw in the AER. The detergent tank was contaminated and once it is contaminated it was not possible to disinfect it.


5.31. Unusual implication of biopsy forceps in outbreaks of *Pseudomonas aeruginosa* infections and pseudo-infections related to bronchoscopy, France, January – April 2003

Between January and April 2003, it was observed at the University Teaching Hospital of Montpellier, France an increase in positive respiratory tract samples for *Pseudomonas aeruginosa*. The samples were cultured from patients who had a bronchoscopic procedure. 61 bronchoscopic procedures were performed in 36 patients with two different bronchoscopes. 16 patients became infected and the infections were traced back to two bronchoscopes. After inspecting the bronchoscopes damage to the internal channel was observed. This damage was caused by defective biopsy forceps and prevented proper cleaning and disinfection of the bronchoscopes. The outbreaks stopped after the inner channels was replaced, and the hospital switched to disposable biopsy forceps.


5.32. Multidrug-Resistant *Pseudomonas aeruginosa* Cholangitis after ERCP, Illinois, July 2002

In July 2002, three patients developed sepsis due to a *Pseudomonas aeruginosa* infection at Northwestern University Feinberg School of Medicine in Chicago, Illinois. All three patients had previously received ERCP treatment. This small outbreak was surprising because Northwestern is diligent about routine surveillance of their endoscopes. The infection control investigators believed that all three patients had received their ERCP treatment with the same scope. They confirmed that hypothesis by testing all of the available scopes and linked the isolates from the patients to the isolates from one scope. This scope had been cultured about a month prior, and the culture was negative for bacterial growth. With that being said, it is possible that infections can still occur even if the surveillance cultures are negative. The screening and surveillance processes have to become more stringent to prevent infections from occurring.

Fraser, T. (2013). *Multidrug-Resistant Pseudomonas aeruginosa Cholangitis After Endoscopic Retrograde Cholangiopancreatography: Failure of Routine Endoscope Cultures to Prevent an Outbreak.* *Infection Control and Hospital Epidemiology, 25(10), 856-859.*

At Johns Hopkins Hospital in Baltimore, approximately 1000 flexible bronchoscopic procedures are performed yearly. More than half of the procedures include bronchoalveolar lavage, where sterile saline is instilled in the lower airways and then extracted to obtain samples. Between June 2001 and January 2002, the rate of isolation of *P. aeruginosa* from bronchoalveolar-lavage samples was three times higher than the usual rate. 414 patients had a bronchoscopy during the outbreak. It involved 48 infections of the upper and lower respiratory tracts and bloodstream among 39 of the 414 patients. In 66.7% of these infections *P. aeruginosa* was found. The contaminated bronchoscopes might have been related to a loose biopsy-port cap which could have had a part in the death of three patients.


5.34. An outbreak of multidrug-resistant *Pseudomonas aeruginosa* infection associated with contamination of bronchoscopes and an endoscope washer-disinfector, England, October – November 1998

In the course of a two-month period at the St Thomas Hospital in London between October and November 1998, two strains of *P. aeruginosa* were isolated from eight patients on the intensive care unit and three patients from other units. 11 patient’s cultures came from respiratory samples and eight of the patients had a bronchoscopy. The possible cause of the outbreak appeared that the hospital purchased automated, closed washer-disinfectors due to the health and safety concerns over the use of open-trough glutaraldehyde. The machine had lime scale and biofilm deposits on its internal plumbing. 20 out of 21 samples from the washer-disinfector showed various bacterial contaminants including *Pseudomonas*. 1 specimen grew *P. aeruginosa*. Once the washer-disinfector was removed from service and the bronchoscopes had been cleaned, there was no patient cultures identified with ceftazidime- and azlocillin-resistant *P. aeruginosa*.


5.35. Nosocomial Transmission of *Pseudomonas aeruginosa* Following Bronchoscopy Associated with Improper Connection to the STERIS SYSTEM 1 Processor, New York, August - October 1998

This paper discusses the outbreak of Imipenem-Resistant *P. aeruginosa* (IRPA) after bronchoscopy procedures in the New York Hospital Medical Center of Queens in August, September, and October of 1998. IRPA was found in 18 patients total. Using traditional and molecular techniques, the investigators cultured multiple spots on bronchoscopes, cleaning equipment, and tubing. The results show that there was no direct patient-to-patient transmission. The likely cause of the infections was
endoscopes used for the bronchoscopy procedure. The investigators linked the outbreak to poor training on new AERs for the disinfection staff as well as the similar, yet different connectors found on the new AERs compared to the old AERs.


Medical equipment pieces like fiber-optic scopes cannot withstand high temperatures; it then becomes hard to accomplish high-level disinfection or sterilization. Automated washers using 2% glutaraldehyde to reach high-level disinfection are commonly used to clean fiber-optic scopes. These washers can be contaminated with atypical mycobacteria, including Mycobacterium chelonae. In August of 1998, the microbiology laboratory reported an unusual number of acid-fast bacilli and pink bacteria identified as M. chelonae and M. mesophilicum during the cultures obtained during bronchoscopy. Between July 21st and October 2nd 1998, 26 of 131 fungal cultures obtained by bronchoscopy grew M. chelonae. The 26 cultures obtained came from 22 patients. Two of the 22 cases were not thought to be part of the outbreak. The automated washers were the result of the contaminations. The washers then contaminated the endoscopes and the bronchoscopes that were used to decontaminate. As a result, the medical center purchased new endoscopes and a new peracetic acid sterilization system.